Introduction {#s1}
============

Pattern recognition receptors (PRRs) are germline-encoded proteins expressed primarily on innate immune cells that recognize conserved microbe- or pathogen-associated molecular patterns (PAMPs), and damage-associated molecular pattern (DAMPs). The main paradigm of immune activation posits that triggering of PRRs results in the maturation of DCs and their subsequent activation-acquired properties to elicit and shape CD8^+^ T cells and CD4^+^ Th cells responses ([@bib30]; [@bib75]; [@bib94]). DCs, the main antigen presenting cells (APCs), display migratory and functional heterogeneity, and are distributed throughout the body ([@bib28]). Conventional DCs (cDCs) are found in most tissues and thought to be of two major lineages, each of which expresses a distinctive set of surface receptors and a unique set of TFs that regulate development and function of DCs ([@bib28]; [@bib67]). For example, the splenic cDC1 subpopulation, which promotes CD4^+^ Th1 and CD8^+^ cytotoxic T cells (CTL) responses, requires the TFs interferon regulatory factor 8 (IRF8) and basic leucine-zipper ATF-like transcription factor 3 (BATF3), whereas splenic cDC2s, which promote Th2 and Th17 responses, require IRF4 ([@bib23]; [@bib29]; [@bib97]; [@bib104]) and Kruppel-like factor 4 (KLF4) ([@bib95]). The cDC2s lineage has been further divided into Th2-inducing (IRF4^+^/KLF4^+^), and Th17-inducing (IRF4^+^/NOTCH2^+^) subpopulations ([@bib7]; [@bib95]). These cDCs express many PRRs to trigger DC maturation but can elicit and shape the CD4^+^ Th response in the absence of such stimulation. DCs also express multiple G protein-coupled receptors (GPCRs) but their role, in particular of GPCRs that regulate cAMP formation, in DC-related innate immunity and hence, on adaptive immunity, is poorly understood ([@bib35]; [@bib78]). Thus, even though cAMP regulates many biological processes, its impact on immune responses is not well defined.

IRF4 influences B and T lymphocyte antigen-dependent responses by controlling the effector properties of expanded clones ([@bib19]; [@bib34]). Induced as an immediate early gene by antigen receptors, IRF4's expression scales with the intensity of receptor signaling, thus linking the quality of antigen receptor signaling with B and T cell fate output ([@bib44]; [@bib56]; [@bib58]; [@bib72]; [@bib74]; [@bib85]; [@bib109]). Differing concentrations of IRF4 induced by antigen receptor signaling are thought to promote differential assembly of IRF4 into distinct TFs and DNA recognition complexes to regulate gene expression programs important for B and T cell fate ([@bib44]; [@bib74]). In contrast to other members of the IRF family, expression of IRF4 is not induced by either Type I or Type II interferon ([@bib58]) but rather by different modes of NF-kB signaling induced by the antigen receptors, TLR, and TNF receptor systems ([@bib87]). IRF4 plays important roles in controlling the stimulatory properties of DCs but the mechanisms and contexts by which these are deployed to regulate Th responses are less well understood ([@bib4]; [@bib97]).

We have found that low levels of cAMP in cDCs promote Th2 differentiation ([@bib50]) and high levels promote induction of Th17 ([@bib18]). In the current study, we sought to dissect the molecular mechanisms by which cAMP levels regulate these Th responses by cDC1 and cDC2 subsets and identified a previously unappreciated DC plasticity provoked by PRR-independent (cAMP) and PRR-dependent (curdlan) signaling that affects Th bias.

Overall, these findings implicate a previously unappreciated DC plasticity provoked by PRR-independent (cAMP) and PRR-dependent (curdlan) signaling that affects Th bias.

Results {#s2}
=======

Cyclic AMP signaling reprograms cDC2 cells from a pro-Th2 to a pro-Th17 phenotype {#s2-1}
---------------------------------------------------------------------------------

We previously reported that cAMP signaling in CD11c^+^bone marrow derived DCs (BMDCs), that is, BM-derived antigen presenting cells (BM-APCs), affects the differentiation of CD4^+^ T cells ([@bib18]; [@bib50]). Low cAMP levels, as occurs in the mice with deletion of *Gnas* in CD11c-expressing cells (Gnas^ΔCD11c^ mice, generated by breeding of *Gnas* floxed mice (Gnas^fl/fl^) with CD11c-Cre mice), provoke a Th2 polarization that leads to an allergic phenotype ([@bib50]), while cholera toxin (CT) and other treatments that increase cAMP levels in CD11c^+^ cells, induce differentiation to Th17 cells ([@bib18]). Given these observations, it was important to investigate how this phenotypic reprogramming occurs in *bona fide* DCs.

Splenic DCs have been divided into three subsets: two cDC subsets (cDC1s and cDC2s), and plasmacytoid DCs (pDCs) ([@bib28]; [@bib90]). We tested the effect of the cell-permeable cAMP analog 8-(4-Chlorophenylthio) adenosine 3\',5\'-cyclic monophosphate (CPT) on cDC2s and cDC1s. cDC2s (CD11c^+^CD11b^+^CD8α^-^ splenocytes) ([@bib32]) were isolated by FACS sorting, pulsed with MHC class II (MHCII) OVA peptide and co-cultured with naïve OVA-specific splenic OT-II CD^4+^ T cells (OT-II cells). Treatment of WT cDC2s with CPT decreased IL-4 ([Figure 1A](#fig1){ref-type="fig"}) and increased IL-17A concentrations ([Figure 1B](#fig1){ref-type="fig"}) in co-cultured OT-II cells. IFN-γ and IL-10 concentrations were not changed by CPT-treated cDC2s ([Figure 1C,D](#fig1){ref-type="fig"}). Analysis of the T cell lineage commitment factors of OT-II cells co-cultured with CPT-treated cDC2s revealed a decrease in *Gata3* and increase in *Nr1f3* levels ([Figure 1E](#fig1){ref-type="fig"}). Induction of IL-17 by CPT-treated cDC2 was 2-fold greater in IL-17 GFP OT-II cells ([Figure 1F](#fig1){ref-type="fig"}). The TFs *Irf4* ([@bib23]; [@bib104]) and *Klf4* ([@bib95]) regulate the pro-Th2 phenotype of DCs. CPT decreased the expression of *Irf4* and *Klf4* in cDC2s in a time-dependent manner; *Irf8* expression was not affected. To verify that cAMP signaling was activated, we assessed expression of the cAMP-induced gene *Crem* and observed a time-dependent, 10-fold induction ([Figure 1G](#fig1){ref-type="fig"}). Decreased expression of IRF4 after CPT treatment was confirmed by intracellular FACS staining ([Figure 1H](#fig1){ref-type="fig"}). We also tested the effect of CPT on the transcriptional program of cDC1s, we isolated CD11c^+^CD11b^-^CD8α^+^ splenocytes and co-cultured them with OT-II cells. Unlike what occurred with cDC2s, CPT treatment of cDC1s did not change the T cell cytokines or T cell lineage commitment factors in the co-cultured OT-II cells ([Figure 1---figure supplement 1A--D](#fig1s1){ref-type="fig"}). Furthermore, *Crem* was induced but expression of *Irf4* and *Klf4* was not changed by CPT treatment ([Figure 1---figure supplement 1E](#fig1s1){ref-type="fig"}). cDC2 cells had higher IRF4 ([Figure 1H](#fig1){ref-type="fig"}), IRF5 ([Figure 1---figure supplement 1F](#fig1s1){ref-type="fig"}) and lower IRF8 ([Figure 1---figure supplement 1G](#fig1s1){ref-type="fig"}) compared to cDC1s. Expression of IRF5 and IRF8 was not changed by CPT treatment ([Figure 1---figure supplement 1H,I](#fig1s1){ref-type="fig"}).

![cAMP signaling switches cDC2s to a pro-Th17 bias.\
(**A--D**) IL-4, IL-17A, IFN-γ and IL-10 levels from anti-CD3/28 Ab-stimulated OT-II cells co-cultured with WT splenic cDC2s (CD11c^+^CD11b^+^CD8α^-^) pretreated with or without CPT. (**E**) qPCR analysis of lineage commitment factors in OT-II T cells co-cultured with WT cDC2s in the presence of CPT. (**F**) GFP expression from IL-17GFP OT-II CD4^+^ T cells co-cultured with WT cDC2s pretreated with or without CPT. (**G**) qPCR of TFs in WT cDC2s treated with CPT (50 μM). Two-way ANOVA with Sidak's multiple comparisons test; *n* = 3 in each group, \*\*p\<0.01, \*\*\*p\<0.001. Effect of CPT treatment; *Irf4* (p=0.002), *Klf4* (p\<0.001) and *Crem* (p\<0.001). (**H**) Intracellular staining of IRF4 in WT cDC1 and cDC2s treated with or without CPT for 48 hr. (**I--M**) Fate mapping: IL-17GFP OT-II CD4^+^ T cells were co-cultured with Gnas^ΔCD11c^ BM-APCs to generate memory Th2 cells (1^st^ co-culture). From the 1^st^ co-culture, T1/ST2^+^ cells were FACS sorted and then used for co-culture with WT cDC2s pretreated with or without CPT or Cholera toxin (CT) (2^nd^ co-culture). (**I**) IL-4, (**J**) IL-17A and (**K**) IFN-γ levels, (**L**) qPCR of lineage commitment factors, and (**M**) GFP signal for IL-17 expression in the re-stimulated CD4^+^ T cells from 2^nd^ co-culture. Data are representative of three independent experiments; \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001.](elife-49416-fig1){#fig1}

Memory Th cells are divided into two subsets: effector memory T (TEM, CD44^+^CD62L^low^) and central memory T (TCM, CD44^+^CD62L^high^) cells ([@bib71]). To assess a possible switch in fate from Th2EM to Th17 cells ([@bib33]; [@bib71]), we first generated Th2EM cells by co-culturing naïve IL-17GFP OT-II cells with Gnas^ΔCD11c^ BM-APCs ([@bib50]) and then sorted T1/ST2^+^ cells ([@bib54]). More than 96% of T1/ST2^+^ cells from the co-culture were Th2EM and FOXP3^-^ ([Figure 1---figure supplement 2A](#fig1s2){ref-type="fig"}). The sorted cells were then used for a second co-culture with CPT- or cholera toxin (CT) ([@bib18])-treated WT cDC2s. Th2EM co-cultured with CPT- or CT-treated WT cDC2s had decreased expression of IL-4 ([Figure 1I](#fig1){ref-type="fig"}), increased IL-17A expression ([Figure 1J](#fig1){ref-type="fig"}) but unchanged expression of IFN-γ ([Figure 1K](#fig1){ref-type="fig"}). Th2EM co-cultured with CPT- or CT-treated cDC2s had altered expression of T cell lineage commitment factors: decreased expression of *Gata3* and increased expression of *Nr1f3* and *Nr1f1* ([Figure 1L](#fig1){ref-type="fig"}). CPT- or CT-induced Th17 differentiation was confirmed by GFP expression (FACS) in re-stimulated OT-II cells ([Figure 1M](#fig1){ref-type="fig"}). Expression of T1/ST2 and memory T cell markers, CD62L and CD44, was FOXP3^-^ ([Figure 1---figure supplement 2B](#fig1s2){ref-type="fig"}) but not changed by the second co-culture (data not shown). Overall, these findings suggest that these cells are akin to Th2-Th17 hybrid cells ([@bib98]).

To confirm these effects in a genetic model, we isolated CD11c^+^CD11b^+^CD8α^-^ splenocytes from Gnas^fl/fl^ and Gnas^ΔCD11c^ mice (which have a prominent decrease in expression of the Gαs protein and in cAMP synthesis and as a result, a bias toward Th2 induction) ([@bib50]) and tested the cDC2 in co-culture with OT-II cells. We found that cDC2s from Gnas^ΔCD11c^ mice elicited a 9.7-fold greater IL-4 response, which was completely suppressed by CPT treatment ([Figure 1---figure supplement 3A](#fig1s3){ref-type="fig"}). IL-17A response induced by CPT-treated Gnas^ΔCD11c^ cDC2s increased by 3.4-fold and 2.6-fold in CPT-treated Gnas^fl/fl^ cDC2 ([Figure 1---figure supplement 3B](#fig1s3){ref-type="fig"}). Treatment with CPT suppressed *Gata3* and induced higher *Nr1f3* levels in co-cultured OT-II cells without altering *Tbx21* or *Foxp3* ([Figure 1---figure supplement 3D](#fig1s3){ref-type="fig"}). Basal *Irf4* and *Klf4* levels in cDC2s were elevated in the Gnas^ΔCD11c^ compared to Gnas^fl/fl^ cDC2 but were suppressed in response to CPT ([Figure 1---figure supplement 3E,F](#fig1s3){ref-type="fig"}). CPR treatment induced *Crem* but did not change *Irf8* expression ([Figure 1---figure supplement 3E](#fig1s3){ref-type="fig"}).

To confirm that BM-APCs are a valid model for DC reprogramming and to gain further insight into mechanisms underlying this process, we tested WT CD11c^+^CD135^+^ BM-APCs. Agonists that increase cAMP induced a pro-Th17 phenotype in BM-APCs ([Figure 1---figure supplement 4A,B](#fig1s4){ref-type="fig"}) and a 2-fold increase in *Nr1f3* expression ([Figure 1---figure supplement 4C](#fig1s4){ref-type="fig"}). Expression of *Irf4* and *Klf4* was also decreased by treatment of WT BM-APCs with agonists that increase cAMP ([Figure 1---figure supplement 4D](#fig1s4){ref-type="fig"}). We assessed the impact of three cAMP signaling effectors, PKA ([@bib26]), EPAC ([@bib77]), and CREB ([@bib107]), in the inhibition of *Irf4* by PGE2, a Gαs-coupled GPCR agonist ([@bib102]). Treatment with Rp-cAMP (a PKA inhibitor) or 666--15 (a CREB inhibitor) but not with CE3F4(an EPAC inhibitor) abolished the PGE2-promoted reduction in *Irf4* expression ([Figure 1---figure supplement 4E,F](#fig1s4){ref-type="fig"}).

We also assessed the effect of cAMP treatment on human DC-like cell lines generated from MUTZ-3 (myelomonocyte) ([@bib62]), THP-1 (monocyte) ([@bib8]), and HL-60 (promyeloblast) ([@bib42]). As observed with mouse cDC2s or BM-APCs, the human DC-like cells responded to CPT with a decrease in expression of *Irf4* and *Klf4* ([Figure 2](#fig2){ref-type="fig"}).

![Decreased expression of *Irf4* by CPT in human DC-like cells DC-like cells were differentiated from (**A**) MUTZ-3, (**B**) THP-1, and (**C**) HL-60 cell lines and treated with CPT for the indicated time.\
Relative expression of *Irf4*, *Klf4*, and *Crem* were analyzed. Data are representative of three independent experiments; Two-way ANOVA \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001.](elife-49416-fig2){#fig2}

Collectively, these results indicate that increased cAMP levels reprogram transcription of cDC2s and BM-APCs from WT and Gnas^ΔCD11c^ mice. Low cAMP concentrations promote expression of a pro-Th2 phenotype while high cAMP concentrations promote pro-Th17 inducing properties and a subsequent switch from Th2 to Th17 bias. Furthermore, high cAMP concentrations can override an existing pro-Th2 phenotype and reprogram cDC2 into pro-Th17-inducing cDC17s. This phenotypic switch in DC2s is mediated by cAMP signaling via PKA/CREB, but not EPAC, and is associated with the inhibition of *Irf4* and *Klf4*.

PRR-dependent signaling down-regulates IRF4 and KLF4 expression and induces a pro-Th17 phenotype of DCs {#s2-2}
-------------------------------------------------------------------------------------------------------

To investigate if the reprogramming of WT cDC2 is specific for cAMP signaling, we tested the effect of a microbial Th17 inducer, curdlan. Curdlan is a linear polymer of β (1,3)-glucan derived from soil bacteria and the ligand of the PRR Dectin-1 ([@bib110]). Signaling by Dectin-1 is independent of cAMP and involves recruitment of Syk to the Dectin-1 intracellular tail, followed by activation of MAPK, NF-κB and NFAT ([@bib27]) and induction of IL-23, which promotes Th17 differentiation ([@bib52]; [@bib81]). WT cDC2s express Dectin-1 ([Figure 3A](#fig3){ref-type="fig"}). Treatment of these cells with curdlan increased IL-17A concentrations 2.5-fold ([Figure 3B](#fig3){ref-type="fig"}) and *Nr1f3* mRNA levels 1.7-fold ([Figure 3C](#fig3){ref-type="fig"}) in co-cultured OT-II cells. Akin to what occurred with CPT treatment, curdlan inhibited the expression of *Irf4* and *Klf4*, but not *Irf8,* in cDC2s ([Figure 3D](#fig3){ref-type="fig"}) and induced *Il23a* ([@bib1]) 6-fold ([Figure 3E](#fig3){ref-type="fig"}). The increase in IL-17A in curdlan-treated cDC2s was blocked by the CREB inhibitor, 666--15, but not by the PKA inhibitor, Rp-cAMP ([Figure 3F,G](#fig3){ref-type="fig"}). Unlike cDC2s, cDC1s cells do not express, or express very low levels of Dectin-1 ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). Accordingly, curdlan treatment of cDC1s did not change the expression of T cell cytokines in co-cultured OT-II cells ([Figure 3---figure supplement 1B,C](#fig3s1){ref-type="fig"}), nor that of *Irf4* and *Il23a* in cDC1s ([Figure 3---figure supplement 1D,E](#fig3s1){ref-type="fig"}). Overall, these data indicate that curdlan acts via its PRR to induce a Th17 bias by cDC2s by a CREB-dependent, cAMP-PKA-independent pathway. Furthermore, the PRR-mediated and cAMP-mediated activation pathways converge on CREB to provide phenotypic plasticity of DCs, thus defining a new basis for classification of novel cDC2 and cDC17 subsets.

![Stimulation of DCs via Dectin-1 (a PPR) regulates IRF4 and KLF4 expression, and induce Th17 differentiation.\
(**A**) Expression of Dectin-1 on WT cDC2s. Numbers indicate mean fluorescence intensity (GeoMFI). (**B**) IL-17A levels produced by OT-II cells co-cultured with WT splenic cDC2s treated with or without curdlan (10 μg/ml). (**C**) qPCR of lineage commitment factors in OT-II cells co-cultured with curdlan-treated and untreated WT cDC2s. qPCR of (**D**) TFs and (**E**) IL-23 in the WT cDC2s treated with curdlan for the indicated time points. Two-way ANOVA; *n* = 3 in each group. (**F**) IL-17A levels produced by OT-II cells co-cultured with WT BM-APC pre-treated with Rp-cAMP (50 μM), or 666--15 (1 μM) 16 hr prior to curdlan treatment. (**G**) qPCR of *Irf4* in WT cDC2s treated with or without curdlan in the presence of inhibitors of CREB (666--15, 1 μM) or PKA (Rp-cAMP, 50 μM). Two-way ANOVA; *n* = 3 in each group. Data are representative of three independent experiments; \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001.](elife-49416-fig3){#fig3}

Loss of IRF4 or IRF5 in DCs promotes or inhibits, respectively, the pro-Th17 DC phenotype and subsequent Th17 bias {#s2-3}
------------------------------------------------------------------------------------------------------------------

IRF4 is a key TF in the development and function of innate immune cells (macrophages and cDCs) and adaptive immune cells (B and T cells) ([@bib10]; [@bib63]; [@bib83]; [@bib92]). IRF4-deficient cDCs display dysfunctional antigen processing and presentation ([@bib97]) and do not migrate to draining lymph nodes, which may contribute to their inability to stimulate Th2 or Th17 responses ([@bib4]; [@bib97]). The findings above indicate that cAMP signaling in splenic cDC2s inhibits IRF4 expression and provokes a Th17 bias. To determine if inhibition of IRF4 levels affects the pro-Th17 phenotype, we used splenic cDC2s from *Irf4*-inducible (*Irf4^-/-^*) mice ([@bib74]). These *Irf4^-/-^* mice have a tetracycline (tet)-inducible cDNA allele of *Irf4* and the M2rtTA tet-activator allele, hereafter termed Irf4i mice. Doxycycline (Dox) induces IRF4 expression in cDC2s from these mice ([Figure 4A](#fig4){ref-type="fig"}). Unlike WT cDC2s, Irf4i cDC2s pulsed with MHCII OVA peptide (i.e., without any additional stimulation) increased IL-17A and decreased IL-5 production in co-cultured OT-II cells ([Figure 4B,C](#fig4){ref-type="fig"}). Activation of IRF4 with Dox treatment inhibited IL-17A production ([Figure 4B](#fig4){ref-type="fig"}), increased IL-5 levels ([Figure 4C](#fig4){ref-type="fig"}) but IL-4 was not detected and IFN-γ was not affected by the expression of IRF4 in these cDC2s ([Figure 4D](#fig4){ref-type="fig"}). Expression of the T cell lineage commitment factors *Gata3* was increased and *Nr1f3* was decreased in OT-II cells co-cultured with Dox-treated Irf4i cDC2 ([Figure 4E](#fig4){ref-type="fig"}). Dox-treated BM-APCs from Irf4i mice also had increased IRF4 ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}). As with cDC2s, Irf4i BM-APCs induced Th17 differentiation spontaneously and restoring IRF4 expression with Dox treatment inhibited the increase in IL-17 (i.e., Th17) ([Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}). Moreover, restoration of IRF4 expression in BM-APCs induced Th2 differentiation; CPT did not change the restored IRF4 expression and subsequent T cell differentiation ([Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}), implying that sustained expression of IRF4 in DCs can blunt the effects of cAMP on their function. cDC2s from mice with deletion of IRF4 in CD11c-expressing cells (IRF4^ΔCD11c^ mice, generated by breeding of *Irf4* floxed mice (*Irf4*^fl/fl^) with CD11c-Cre mice) also induced Th17 differentiation spontaneously ([Figure 4F](#fig4){ref-type="fig"}), or if treated with CPT or curdlan. However these cells had minimal or no significant increases of IL-1β or IL-6 ([Figure 4G,H](#fig4){ref-type="fig"}), cytokines that provoke Th17 differentiation ([@bib16]).

![Decreased IRF4 expression in cDC2s promotes pro-Th17 phenotype.\
(**A**) IRF4 expression in the Irf4i cDC2s treated with or without doxycycline (Dox, 200 ng/ml) for 16 hr. (**B--D**) IL-17A, IL-5 and IFN-γ levels and (**E**) T cell lineage commitment factors from the re-stimulated OT-II cells co-cultured with cDC2s from WT and Irf4i mice under the conditions described above. (**F**) IL-17A levels from anti-CD3/28 Ab-stimulated OT-II cells co-cultured with IRF4^ΔCD11c^ cDC2s. (**G**) IL-1β and (**H**) IL-6 level in WT and *Irf*^ΔCD11c^ cDC2s after treatment of CPT or Curdlan for 24 hr. Data are representative of three independent experiments; \*p\<0.05, \*\*p\<0.01. (**I**) A schematic diagram of Th2 inhibition and pro-Th17 induction by PRR-independent and -dependent signals.](elife-49416-fig4){#fig4}

IRF5 in macrophages has induces Th17 response ([@bib43]). We thus tested whether IRF5 in cDC2s affects the pro-Th17 phenotype. CPT treatment of OVA-pulsed cDC2 from *Irf5 ^-/-^* mice did not provoke a Th17 response ([Figure 4---figure supplement 2A](#fig4s2){ref-type="fig"}). Even though *Irf4* and *Klf4* levels were inhibited, *Irf8* was unchanged and *Crem* was induced ([Figure 4---figure supplement 2B](#fig4s2){ref-type="fig"}). Thus, even in the absence of IRF4, IRF5 was required for the cAMP-induced pro-Th17 phenotype. *Irf5* levels were similar in *Irf4^-/-^* and WT mice, indicating that IRF5 expression is independent of IRF4.

Overall, these results emphasize that the deletion or substantial inhibition of IRF4 levels in DCs is necessary but not sufficient for provoking Th17 differentiation, and that IRF5 expression in DCs is necessary but insufficient for cAMP to provoke Th17 bias.

IRF4 mediates cAMP-promoted transcriptional events {#s2-4}
--------------------------------------------------

To assess the mechanisms for cAMP-PKA-mediated suppression of IRF4 expression, we initially performed transcriptional profiling (RNAseq) of untreated or CPT-treated splenic cDC2s from WT mice, global *Irf4* KO mice (*Irf4^-/-^*), and Irf4i mice treated with Dox. Treatment of splenic cDC2s from WT mice with CPT altered expression of 2991 genes (FDR \< 0.05, [Figure 5A](#fig5){ref-type="fig"}), results resembling those previously observed for BM-APCs ([@bib18]). Expression of 2454 genes was significantly altered in *Irf4^-/-^* cDC2 s compared to WT cDC2s but expression of only 1401 genes was altered in *Irf4^-/-^* cDC2 s with restored expression of *Irf4* (Dox) ([Figure 5A](#fig5){ref-type="fig"}; [Supplementary file 1](#supp1){ref-type="supplementary-material"}: containing Supplementary Tables 1-3). Surprisingly, only 24% of the genes altered in the *Irf4*^-/-^ cDC2s were restored by re-expression of IRF4 in Dox-treated Irf4i cells, and only 42% of the Dox-dependent genes were altered in the *Irf4*^-/-^ cells. These results are not related to the stringency of the multiple testing correction as the discordance remained (30% and 46%, respectively) even without a correction for FDR. The findings are consistent with prior data for genes that display a bimodal pattern of expression as a function of IRF4 concentration in B and T cells ([@bib37]; [@bib44]; [@bib74]).

![CPT and IRF4 transcriptomic effects and analysis of genome-wide binding of IRF4, CREB and KLF4.\
(**A**) Venn diagram showing overlap of genes altered by CPT treatment (50 µM, 16 hr) of WT splenic cDC2s, with splenic cDC2s derived from *Irf4*^-/-^ mice, and splenic cDC2s from *Irf4^-/-^* mice that have been induced with Dox (200 ng/ml, 16 hr). (**B**) Heatmap showing expression (log2 fold- change) of the 745 genes common to CPT and *Irf4*^-/-^ cDC2s. Colored bars under the heatmap indicate clusters of genes with similar expression patterns. (**C**) Heatmap showing expression (log2 fold-change) of secreted genes that are altered in *Irf4^-/-^* and Dox datasets. (**D**) Venn diagram showing overlap of CPT-dependent genes with ChIPseq peaks for IRF4, CREB1 and KLF4. (**E**) Metagene analysis of the localized binding of IRF4, CREB1 and KLF4 to a synthetic gene. The synthetic gene is 25 kB in length and is flanked by 25 kB of upstream and downstream sequence. The transcriptional start site is indicated at 0. The plot shows the number of peaks per bp per gene (x10^−3^). (**F**) Co-localization of histone epigenetic modifications H3K4me1, H3K4me3, H3K27ac and H3K9me3 at IRF4, CREB and KLF4 peaks. The graphs show the ChIP fragment depth relative to the center of the TF peak. (**G**) Known transcription factor motifs identified in the IRF4 binding peaks. Height of the letter indicates its conservation. The p-value for the motif and its best match are shown. (**H**) Co-localization of H3K27ac and HeK9me3 modifications at the peaks with the three IRF4 motifs (ISRE, EICE, AICE). (**I**) IRF4, BATF, and PU.1 binding to the IRF4-super enhancer at the *Il6* locus. The *Il6* gene structure is shown at the top and RNAseq reads from untreated and CPT-treated cDC2s are shown in green and blue. Locations of individual motifs are indicated below the binding.](elife-49416-fig5){#fig5}

Transcriptional network analysis showed that the predominant TF driving CPT-dependent genes was Creb1, which appeared to regulate 1134 genes (38%, z-score 236) ([Supplementary file 1](#supp1){ref-type="supplementary-material"}: containing Supplementary Table 4). Unexpectedly, CREB1 was also the major TF 'driver' of genes altered in *Irf4*^-/-^ cells and Dox-treated Irf4i cells (592 and 442 such genes, 24% and 32%, z-scores 233 and 240, respectively) ([Supplementary file 1](#supp1){ref-type="supplementary-material"}: containing Supplementary Tables 5-6). These observations implicate CREB1 as a cofactor for IFR4-regulated genes and suggest a link between cAMP signaling and IRF4-regulated transcription in DCs.

The genes altered by CPT treatment or loss of IRF4 significantly overlapped (p\<0.0001 by Chi-square): 745 genes ([Supplementary file 1](#supp1){ref-type="supplementary-material"}: containing Supplementary Table 7) were in common ([Figure 5A](#fig5){ref-type="fig"}), a greater number than between the *Irf4^-/-^* and Dox-treated cells (585 genes, [Supplementary file 1](#supp1){ref-type="supplementary-material"}: containing Supplementary Table 8). Clustering analysis revealed distinct classes of changes among the 745 common genes ([Figure 5B](#fig5){ref-type="fig"}). A large cluster of genes was concordantly induced ([Figure 5B](#fig5){ref-type="fig"} magenta) and a smaller cluster of genes was reduced ([Figure 5B](#fig5){ref-type="fig"} green) by CPT or loss of IRF4, with opposite responses by IRF4 re-expression. These two clusters may indicate genes indirectly regulated by cAMP via its suppression of IRF4 expression. Examples of genes in these clusters are the IL-1 receptor antagonist (*Il1rn)* and C-C motif chemokine receptor 2 (*Ccr2)* ([Figure 5---figure supplement 1A,B](#fig5s1){ref-type="fig"}). Other clusters are discordant. that is, decreased by CPT but increased in the *Irf4^-/-^* cells or vice versa ([Figure 5B](#fig5){ref-type="fig"}, green and orange). Examples of genes in these clusters are plasminogen activator, urokinase receptor (*Plaur)* and matrix metalloprotease 27 (*Mmp27*) ([Figure 5---figure supplement 1C,D](#fig5s1){ref-type="fig"}).

Since CPT treatment, loss of IRF4 or restoration by Dox treatment all changed the ability of cDC2s to promote Th bias, we reasoned that key mediators of this bias would be among the 236 genes that were common to the three datasets ([Supplementary file 1](#supp1){ref-type="supplementary-material"}: containing Supplementary Table 9). Transcriptional network analysis and enrichment analysis for pathways and processes of these 236 common genes revealed that the most significantly enriched TF was CREB1 ([Supplementary file 1](#supp1){ref-type="supplementary-material"}: containing Supplementary Table 10) and the most significantly enriched pathways related to cell adhesion, CCL2 signaling, immune cell migration, myeloid differentiation, neutrophil activation, and inter-cellular interactions in COPD ([Supplementary file 1](#supp1){ref-type="supplementary-material"}: containing Supplementary Table 11). Network enrichment of processes centered on angiogenesis and immune cell activation/response pathways ([Supplementary file 1](#supp1){ref-type="supplementary-material"}: containing Supplementary Table 11). The two highest enriched GO processes were secretion-related (p\<10^−25^), suggesting involvement of secreted mediators of Th differentiation ([Supplementary file 1](#supp1){ref-type="supplementary-material"}: containing Supplementary Table 11). We therefore intersected this group of genes with curated and highly-likely predicted secreted proteins from the MetazSecKB database ([@bib59]) and found that secreted proteins were highly enriched (59 of the 236 common genes (25%), p\<0.0001). We subdivided these genes into those with concordant or discordant regulation between CPT treatment and *Irf4*^-/-^ ([Supplementary file 1](#supp1){ref-type="supplementary-material"}: containing Supplementary Table 12). Of the 22 concordant genes among the data sets, all were up-regulated by treatment with CPT or in *Irf4*^-/-^, suggesting that promotion of Th17 differentiation requires production of a Th17 mediator rather than loss of a Th2 mediator. Since the loss of *Irf4* can lead to Th17 differentiation, we inspected the secreted genes for ones induced by IRF4 loss and restored by IRF4 'rescue' ([Figure 5C](#fig5){ref-type="fig"}). We also intersected the differentially expressed genes with predicted plasma membrane proteins and found that these are significantly enriched (82 of the 236 common genes (34%), p\<0.0001) ([Supplementary file 1](#supp1){ref-type="supplementary-material"}: containing Supplementary Table 13). These results imply that many of the cAMP-dependent transcriptional changes may be a consequence of the repression of IRF4 expression. Furthermore, the IRF4- and cAMP-dependent genes are enriched in secreted and plasma membrane proteins that could modulate T cell differentiation.

Transcriptional changes correlate with transcription factor binding but not with alteration in chromatin accessibility {#s2-5}
----------------------------------------------------------------------------------------------------------------------

To gain a better understanding of the genomic events involved in these transcriptional changes, we performed a global ATACseq analysis for changes in chromatin accessibility ([Supplementary file 1](#supp1){ref-type="supplementary-material"}: containing Supplementary Table 14 and [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). We observed no significant differences (after multiple-testing correction \[FDR \< 0.05\]) in ATACseq peaks in CPT-treated WT cDC2. *Irf4*^-/-^ cDC2 had only one significant ATACseq peak (in the *Rasl11a* gene); re-expression of IRF4 caused changes in 9 ATACseq regions. These results suggest that cDC2 plasticity is not accompanied by gross changes in chromatin structure.

We then analyzed ChIPseq datasets derived from IRF4, CREB, KLF4, and histone modifications in BMDC, cDC2 and related cells ([Supplementary file 1](#supp1){ref-type="supplementary-material"}: containing Supplementary Table 15). We examined the co-localization of binding sites for IRF4, CREB and KLF4 within CPT-regulated genes ([Figure 5D](#fig5){ref-type="fig"}). Surprisingly, only 7% of CPT-regulated genes (n = 201) contained CREB binding sites, in contrast to 65% with an IRF4 binding site, 74% with a KLF4 binding site, and 56% with both IRF4 and KLF4 binding sites ([Figure 5D](#fig5){ref-type="fig"}). Combining the expression data with the ChIP data showed that the presence of neither a CREB nor a KLF4 binding site was predictive of up- or down-regulation of expression by CPT treatment) ([Figure 5---figure supplement 2A](#fig5s2){ref-type="fig"}). By contrast, the presence of an IRF4 binding site was predictive of both up- and down- regulation by CPT (p=3.6×10^−5^ and 2.6 × 10^−6^, respectively), implying that cAMP regulation of genes in cDC2 may be mediated by alterations in IRF4 expression. Indeed, 890 of the 2991 CPT-regulated genes (30%) were also regulated by IRF4 loss or over-expression ([Figure 5A](#fig5){ref-type="fig"}). A similar analysis with genes altered in the *Irf4^-/-^* and Irf4i cells revealed that IRF4-regulated genes in those cDC2s were not predicted by the presence of a CREB binding site ([Figure 5---figure supplement 2B,C](#fig5s2){ref-type="fig"}), but that up-regulated genes in the *Irf4^-/-^* cells and down-regulated genes in the Irf4i cells were highly predicted by IRF4 binding sites (p=6.9×10^−13^ and p=1.7×10^−14^, respectively). IRF4 binding sites were less predictive for genes that were decreased in *Irf4^-/-^* cells (p=0.0012) but were predictive for genes induced by IRF4 over-expression (p=7×10^−6^). The presence of KLF4 binding sites predicted genes that decreased with IRF4 over-expression (p=7.7×10^−5^).

To further understand the transcriptional regulation, we analyzed the location of the IRF4, CREB and KLF4 binding sites relative to the transcriptional start sites (TSS) and the gene bodies, as well as 25 Kb upstream and downstream of the genes. Both CREB and KLF4 primarily bound to the TSS with very little binding to the gene body, upstream or downstream regions. In contrast, IRF4 showed weaker binding to the TSS but more substantial binding upstream and downstream of the genes ([Figure 5E](#fig5){ref-type="fig"}). Consistent with this observation, the IRF4, CREB and KLF4 binding sites were associated with H3K4me3 and H3K27ac marks of transcriptionally active promoters ([@bib38]) but only IRF4 binding sites were associated with the H3K4me1 modification, which is indicative of enhancers, and with the repressive H3K9me3 modification in the middle of the IRF4 peak ([Figure 5F](#fig5){ref-type="fig"}).

We investigated the known TF motifs bound by IRF4 and found that they fell into three categories: 50% of the sites had ETS:IRF motifs similar to proposed EICEs ([@bib14]; [@bib74]), 24% had duplicated IRF motifs similar to ISREs ([@bib13]; [@bib74]), and 23% had bZIP motifs similar to AICEs ([Figure 5G](#fig5){ref-type="fig"} and [Figure 5---figure supplement 3A](#fig5s3){ref-type="fig"}). The sub-populations of IRF4 binding sites had similar association with H3K4me1 and H3K27ac enhancer marks but different co-localizations with histone repressive marks, in that only IRF4 at ISRE sites was associated with the transcriptionally repressive H3K9me3 mark ([Figure 5H](#fig5){ref-type="fig"}). IRF4 may thus regulate gene expression in a context-specific manner as well as by differential binding dynamics dependent on its interactions with its binding partners ([@bib44]; [@bib74]).

Given this difference in association with transcriptionally repressive histone modifications, we performed a similar analysis with transcriptional changes in response to treatment with CPT ([Figure 5---figure supplement 3B](#fig5s3){ref-type="fig"}). The presence of an AICE most strongly predicted up-regulation by CPT treatment (p=1.7×10^−6^), whereas all three response elements predicted up-regulation in *Irf4^-/-^* cells, and down-regulation in Dox-treated cells. Thus, all three sites may mediate repression by IRF4. The AICE and ISRE, but not the EICE, also predicted gene induction in the Irf4i cells, suggesting that these two elements can confer gene induction by IRF4 ([Figure 5---figure supplement 3B](#fig5s3){ref-type="fig"}). Many of the IRF4 sites clustered together. Using the Young lab criteria, we found evidence for 106 super enhancers with multiple IRF4 binding sites ([Supplementary file 1](#supp1){ref-type="supplementary-material"}: containing Supplementary Table 16) ([@bib103]). Inspection of these super enhancers revealed that one was located in the *Il6* locus and had multiple binding sites for IRF4, BATF and PU.1; these peaks corresponded to EICEs, AICEs and ISREs identified in the motif analysis ([Figure 5I](#fig5){ref-type="fig"}). Localization of IRF4, CREB, KLF4, H3K4me3 and H3K27ac peaks and the presence of open chromatin (measured by ATACseq) in the vicinity of the *Irf4* and *Klf4* genes indicated that the *Klf4* gene, but not the *Irf4* gene, may be a direct target for CREB ([Figure 5---figure supplement 4](#fig5s4){ref-type="fig"}).

These genomic data were thus consistent with a role for IRF4 binding to and regulation of cAMP- and IRF4-dependent genes. The results also suggested that CREB does not directly regulate many of these cAMP-dependent genes. The data also implied that IRF4-dependent transcriptional events are modulated by the partner TF as IRF4 homodimers or heterodimers with ETS or bZIP proteins predicted to contribute to gene repression, but only IRF4 homodimers and bZIP heterodimers mediating gene induction.

Adoptive transfer of HDM-pulsed, CPT- or curdlan-treated cDC2s induce a Th17 bias and neutrophilic infiltration {#s2-6}
---------------------------------------------------------------------------------------------------------------

We hypothesized that activation of DCs via the cAMP pathway would modify their Th-inducing properties in vivo. To test this hypothesis, we evaluated the impact of CPT on DCs in the induction of Th17 bias by using DC-based adoptive transfer ([@bib48]) ([Figure 6A](#fig6){ref-type="fig"}). HDM- and curdlan-treated cDC2s served as negative and positive controls, respectively, of Th17 induction. Intranasal (i.n.) transfer of HDM-pulsed, CPT-treated or curdlan-treated WT cDC2s followed by HDM i.n challenge increased the production of IL-17A in the lung and airway of WT recipient mice ([Figure 6B,C](#fig6){ref-type="fig"}). However, we did not observe differences in levels of IL-4 (\>0.04 ng/ml) or IFN-γ (\>0.02 ng/ml) in the various groups. We detected an increased number of neutrophils in the bronchoalveolar lavage (BAL) fluid ([Figure 6D--G](#fig6){ref-type="fig"}) and expression of *Cxcl2* and *Cxcl3*, whose expression accompanied neutrophilic infiltration in the CPT- or curdlan-treated cDC2 groups ([Figure 6H](#fig6){ref-type="fig"}). Expression of eosinophilic infiltration-related genes, *Cd24a* and *Dpp4*, was decreased in those groups ([Figure 6H](#fig6){ref-type="fig"}). CPT- or curdlan-treated WT cDC2s transferred to WT recipient mice also had increased airway resistance ([Figure 6I](#fig6){ref-type="fig"}). CPT or curdlan treatment of OVA-pulsed cDC2s ex-vivo prior to their i.n transfer yielded a pattern similar to that observed for HDM ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). Induction of Th17 in the lungs by CPT or curdlan with two different antigen systems thus yielded a shift from a Th2 toward Th17 pulmonary response with a mixed eosinophil/neutrophil inflammatory infiltrate.

![Adoptive transfer of HDM-pulsed, CPT or curdlan-treated cDC2 induces a Th17 bias and neutrophil infiltration in WT recipients.\
(**A**) Schematic of adoptive transfer protocol. WT cDC2s were incubated with HDM (50 μg/ml) in the presence of CPT or curdlan prior to i.n. transfer to WT mice (B6 mice, 1 × 10^6^ cells/recipient) on day 0 and 14. HDM (12.5 µg/mouse) was used for the i.n. challenge on days 19, 20 and 21. On day 22, lungs from each group were harvested and processed a single cell suspension. (**B**) IL-17A level in the HDM (50 μg/ml)-stimulated lung cells. BAL fluid was analyzed for (**C**) IL-17 level (ELISA). (**D**) Total cells (**E**) neutrophils, (**F**) macrophages and (**G**) eosinophils number were counted in the BAL fluid. (**H**) Relative expression of Neut (*Cxcl2* and *Cxcl3*)- and/Eos (*Cd24a* and *Dpp4*)- infiltration related genes in the lung tissue. Expression of each gene was normalized by expression of epithelial specific housekeeping gene, *Epcam*. (**I**) Airway resistance after MCh challenge was measured in the various experimental groups. Data were collected from four animals in each group and are representative of two independent experiments; \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001 by two-tailed Student's t-test.](elife-49416-fig6){#fig6}

Discussion {#s3}
==========

The dominant role of PRRs has been the paradigm for the activation and maturation of DCs with resultant antigen processing and presentation, up-regulation of co-stimulatory molecules, and secretion of cytokines and other immunomodulatory factors; such factors contribute to the differentiation of naïve T cells to effector subpopulations, such as CTL or Th subsets ([@bib2]; [@bib60]). Our results indicate that cAMP, via a PRR-independent pathway, and the microbial product, curdlan, via a PRR-dependent pathway, converge on CREB in cDC2s but not cDC1s. Consequently, *Irf4* and *Klf4* levels are repressed, resulting in a pro-Th17 phenotype of cDC2s (i.e., cDC17s). These results define a novel molecular event by which cDC2s undergo re-programming and hence affect Th cell differentiation, that is, the induction of Th2 vs. Th17 bias ([Figures 1](#fig1){ref-type="fig"} and [3](#fig3){ref-type="fig"} and [Figure 1---figure supplement 4](#fig1s4){ref-type="fig"}).

Prior emphasis on the role of IRF4 in DCs have mainly focused on the up-regulation of IRF4 expression. In the current studies, we discovered that IRF4 expression is repressed by cAMP or curdlan signaling. DCs signaled in this manner skew the consequent T cell responses towards the Th17 effector lineage. In contrast, when DCs signal through FcγRIII, IRF4 expression is up-regulated and leads those DCs to skew T cell responses towards a Th2 effector lineage ([@bib104]). The current results thus identify cAMP-PKA-CREB signaling as a non-PRR pathway that reprograms DCs toward Th17, results that complement evidence that reduced cAMP signaling in DCs provokes Th2 differentiation ([@bib50]). Furthermore, increasing the cAMP concentration in pro-Th2 cDC2s can switch them toward the cDC17 phenotype. DCs thus appear to integrate stimuli from their extracellular environment to control their expression of IRF4, which in turn, regulates the ensuing T cell response.

The effects of cAMP were observed in two different types of DCs; splenic cDC2s and BM-APCs but not in cDC1s cells ([Figure 1](#fig1){ref-type="fig"} and [Figure 1---figure supplements 1](#fig1s1){ref-type="fig"} and [4](#fig1s4){ref-type="fig"}) and are achieved by the inhibition of *Irf4* and *Klf4,* TFs that are prerequisites for the pro-Th2 DC phenotype of cDC2 ([@bib23]; [@bib95]; [@bib104]). cDC2s from Gnas^ΔCD11c^ mice (cells with prominently decreased cAMP signaling) have higher levels of *Irf4* and *Klf4* than do cDC2s from WT mice ([Figure 1---figure supplement 4](#fig1s4){ref-type="fig"}). The *Irf4* and *Klf4* transcript and IRF4 protein levels were inhibited by multiple agonists that increase cAMP and by curdlan (cAMP-independent) activation of the PRR Dectin-1 in WT cDC2s, results that suggest convergent signaling to inhibit *Irf4* and *Klf4* for the cDC17 phenotype ([Figure 3](#fig3){ref-type="fig"}). Based on previous data ([@bib7]; [@bib79]; [@bib84]), we were surprised that BM-APCs and cDC2s from two mouse strains in which IRF4 had been genetically-deleted could provoke a strong Th17 response in the presence of very low IL-1 and IL-6 secretion, suggesting that this pathway of Th17 induction is independent of these cytokines ([Figure 4F--H](#fig4){ref-type="fig"}). Curdlan provoked neither cAMP synthesis nor PKA phosphorylation, but activates CREB ([@bib22]), possibly via MAPK signaling ([@bib39]). We confirmed by using adoptive transfer that pro-Th17 DCs induction by cAMP-independent or PRR-dependent signaling pathways resulted in increased neutrophils and IL-17A production in the airway ([Figure 6](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}).

Our results thus indicate that: 1) inhibition of the pro-Th2 DC cDC2 phenotype by cAMP agonists promotes induction of the pro-Th17 DC cDC17 phenotype, and 2) reduction of IRF4 levels is necessary but not sufficient for induction of the pro-Th17 transcriptional program in DCs by both the PRR-dependent and cAMP-dependent signaling pathways and by cAMP, also requires IRF5. We propose that cDC2 cells appear to include two subpopulations: cDC17 (CD11c^+^, CD11b^+^, IRF4^-^ or IRF4^low^, IRF5^+^), and cDC2 (CD11c^+^, CD11b^+^, IRF4^+^, KLF4^+^).

Further, our data indicate that endogenous IRF4 is a transcriptional repressor of a subset of cAMP-dependent genes in cDC2s, based on the following: 1) its loss causes up-regulation of cAMP-dependent gene expression, 2) presence of an IRF4 binding site is highly predictive of a gene that is regulated by cAMP, and 3) an IRF4 binding site predicts that a gene increases in *Irf4*^-/-^ cDC2s and decreases in IRF4 restored cells. Overexpression of IRF4 restored the repression of these genes but also induced expression of genes not normally regulated by IRF4. The presence of a KLF4 binding site in the context of IRF4 over-expression predicts down-regulation of gene expression, consistent with the known role of KLF4 as a transcriptional repressor. We found that IRF4 binding sites tended to be associated with enhancers as well as promoters and have three known IRF4 binding motifs (50% EICE, 23% AICE, 24% ISRE). While all three sites were associated with transcriptional activity, only the ISRE was associated with transcriptional repression. The AICE was most strongly associated with up-regulated genes by CPT, perhaps indicating a role for the bZIP binding partner BATF/JUN in this response. We therefore conclude that IRF4 is a major repressor of cAMP-stimulated gene expression in cDCs.

Thus, a portion of cAMP-stimulated genes in cDCs appear to be indirectly regulated via suppression of *Irf4* expression. The mechanism involved in the repression of *Irf4* is unknown. Intriguingly, the orphan nuclear receptor *Nr4a* represses *Irf4* expression in CD8^+^ T cells by binding to multiple sites in the *Irf4* promoter ([@bib73]). OVA-challenged *Nr4a1* KO mice have increased airway inflammation, elevated Th2 cytokines and eosinophils in BAL fluid ([@bib46]). In Leydig cells, cAMP activates expression of *Nr4a1* ([@bib65]) but we find that CPT treatment represses *Nr4a1* expression in cDC2s so this is unlikely to be the mechanism. In contrast, the related family member *Nr4a3* stimulates *Irf4* expression in BMDC ([@bib69]), so NR4A family members may regulate *Irf4* expression through differential recruitment of co-repressor and co-activators. Certain other transcriptional regulators (e.g., NF-κB, NFAT, SP1 and STAT4) activate *Irf4* expression ([@bib6]; [@bib11]; [@bib51]; [@bib88]). How cAMP signaling interacts with these pathways in cDC2s is not known but VIP/cAMP signaling interferes with IL-12/JAK2/STAT4 and NF-κB signaling in T cells and macrophages ([@bib49]; [@bib53]). The regulation could also be epigenetic: expression of *Nr4a1* and *Irf4* are repressed by HDAC7 in naïve T cells ([@bib68]).

Reduction of IRF4 expression by cAMP elevation or genetic knockout induced a number of genes encoding secreted proteins in cDC2s, some of which have roles in Th differentiation and immune regulation. For example, the cAMP- and IRF4-dependent genes Lipocalin-2 (*Lcn2*) ([@bib31]) and Leucine-rich alpha two glycoprotein (*Lrg1*) ([@bib96]) may have functional roles in Th17 differentiation ([Figure 5C](#fig5){ref-type="fig"}), perhaps contributing to the independence of Th17 induction from IL-1 and IL-6 ([Figure 4F--H](#fig4){ref-type="fig"}). Similarly, the *Ebi3* ([@bib100]; [@bib12]; [@bib17]), *Il1rn* ([@bib36]; [@bib82]), *Mmp14* ([@bib5]; [@bib24]), and *Pf4* genes ([@bib25]; [@bib106]) have been implicated in Th17 function, and the *Thbs4* gene is associated with altered lung function ([@bib66]; [@bib76]).

Microbial stimulation most likely does not underlie the cAMP-mediated Th2 and Th17 responses for several reasons: 1) the in vivo Th2 and Th17 differentiation were generated in vitro in the presence of antibiotics, 2) the Gnas^ΔCD11c^ mice were co-housed with Gnas^fl/fl^ littermates, which showed no Th bias, 3) Gnas^fl/fl^ BM-APCs and cDC2s display a WT phenotype under the same conditions and 4) WT and Gnas^ΔCD11c^ BM-APCs and cDC2 could be reprogrammed in vitro to a pro-Th17 phenotype by multiple cAMP-elevating agents (in the presence of antibiotics).

As part of homeostatic regulation, cAMP is regulated by GPCRs that recognize host-derived ligands, such as neurotransmitters, hormones, chemokines, metabolites (e.g., fatty acids, lipid mediators, nucleosides/nucleotides [@bib57]), complement cleavage fragments, cholera ([@bib18]), pertussis and heat-labile toxins ([@bib9]), and bacterial formylated peptides ([@bib15]). Thus, GPCRs that alter cellular cAMP concentrations likely have a role in innate immunity and Th differentiation. However, the current studies do not reveal the physiologically most important GPCR(s) that mediate these responses.

GPCR pathway drugs ([@bib91]) and others that regulate cAMP levels, including cyclic nucleotide phosphodiesterase (PDE) inhibitors, may alter Th2/Th17 bias and potentially may cause immunological side effects, or alter diseases that involve Th2 or Th17 responses. Drugs that increase cAMP levels in DCs perhaps facilitate recovery from bacterial infections such as *K. pneumonia* and *P. aeruginosa,* and fungal infections, for example, *Candida albicans* ([@bib45]), for which Th17 response is beneficial. On the other hand, drugs that decrease cAMP levels in DCs and therefore enhance Th2 immunity, might facilitate treatment of helminth infections. The inhibition of IRF4 by agonists that increase intracellular cAMP may also have implications for other disease settings. IRF4 is a key regulator at multiple steps in B-cell differentiation and development ([@bib40]; [@bib74]; [@bib85]) and is an oncogene in multiple myeloma ([@bib87]), to a lesser degree in Hodgkin and non-Hodgkin lymphomas as well as in chronic lymphocytic leukemia ([@bib11]; [@bib86]; [@bib89]). The current findings suggest that new (or perhaps repurposed) agonists of Gαs-linked GPCR drugs might be beneficial for the inhibition of IRF4 in B-cell derived malignancies.

In summary, the current studies revealed that both cAMP-PKA-CREB and PRR-CREB signaling reprogram DCs by regulating a set of TFs that control cDC2 and cDC17 phenotypes and subsequent Th2 or Th17 bias. These findings thus identify the cAMP pathway as a previously unappreciated PRR-independent, transcriptional mechanism for Th bias by DCs and suggest new therapeutic approaches to control immune responses.

Materials and methods {#s4}
=====================

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                                    Designation                                        Source or\                                               Identifiers                                                               Additional\
  (species) or\                                                                                       reference                                                                                                                          information
  resource                                                                                                                                                                                                                               
  ------------------------------------------------ -------------------------------------------------- -------------------------------------------------------- ------------------------------------------------------------------------- --------------
  Strain, strain background (*Mus musculus*)       C57BL/6J (B6)                                      The Jackson Laboratory                                   RRID:[IMSR_JAX:000664](https://scicrunch.org/resolver/IMSR_JAX:000664)    

  Strain, strain background (*Mus musculus*, B6)   CD11c-Cre                                          The Jackson Laboratory                                   RRID:[IMSR_JAX:008068](https://scicrunch.org/resolver/IMSR_JAX:008068)    

  Strain, strain background (*Mus musculus*, B6)   OT-II                                              The Jackson Laboratory                                   RRID:[IMSR_JAX:004194](https://scicrunch.org/resolver/IMSR_JAX:004194))   

  Strain, strain background (*Mus musculus*, B6)   IL17A-eGFP                                         The Jackson Laboratory                                   RRID:[IMSR_JAX:018472](https://scicrunch.org/resolver/IMSR_JAX:018472)    

  Strain, strain background (*Mus musculus*, B6)   *Irf4*^fl/fl^                                      The Jackson Laboratory                                   RRID:[IMSR_JAX:009380](https://scicrunch.org/resolver/IMSR_JAX:009380)    

  Strain, strain background (*Mus musculus*, B6)   *Gnas* ^fl/fl^                                     Lee Weinstein (NIH)                                      MGI:3609165\                                                              
                                                                                                                                                               PMID: [15883378](https://www.ncbi.nlm.nih.gov/pubmed/15883378)            

  Strain, strain background (*Mus musculus*, B6)   *4Get*                                             Dr. M. Kronenberg (LAI, San Diego, CA)                   RRID:[IMSR_JAX:004190](https://scicrunch.org/resolver/IMSR_JAX:004190)    

  Strain, strain background (*Mus musculus*, B6)   *Irf4*-inducible (*Irf4^-/-^*) (Irf4i)             Dr. R. Sciammas (University of California, Davis)        PMID: [23684984](https://www.ncbi.nlm.nih.gov/pubmed/23684984)            

  Strain, strain background (*Mus musculus*, B6)   *Irf5^-/-^*                                        Dr. I. R. Rifkin (Boston University)                     PMID: [25595782](https://www.ncbi.nlm.nih.gov/pubmed/25595782)            

  Strain, strain background (*Mus musculus*, B6)   *Il17a^-/-^*                                       Dr. Y. Iwakura (The University of Tokyo, Japan)          MGI:2388010\                                                              
                                                                                                                                                               PMID: [12354389](https://www.ncbi.nlm.nih.gov/pubmed/12354389)            

  Cell line (*Homo-sapiens*)                       MUTZ-3                                             Dr. Martin L. Yarmush (Rutgers University, New Jersey)   PMID: [29682279](https://www.ncbi.nlm.nih.gov/pubmed/29682279)            

  Cell line (*Homo-sapiens*)                       THP-1                                              ATCC                                                     RRID:[CVCL_0006](https://scicrunch.org/resolver/CVCL_0006)                

  Cell line (*Homo-sapiens*)                       HL-60                                              ATCC                                                     RRID:[CVCL_0002](https://scicrunch.org/resolver/CVCL_0002)                

  Antibody                                         PE anti-mouse monoclonal CD11c                     eBioscience                                              Cat\# 12-0114-82                                                          FACS (1:200)

  Antibody                                         FITC anti-mouse monoclonal CD11c                   BioLegend                                                Cat\# 117306                                                              FACS (1:200)

  Antibody                                         APC anti-mouse monoclonal CD8α                     BD Bioscience                                            Cat\# 553035                                                              FACS (1:200)

  Antibody                                         FITC anti-mouse monoclonal CD8α                    BD Bioscience                                            Cat\# 553031                                                              FACS (1:200)

  Antibody                                         APC anti-mouse monoclonal CD11b                    eBioscience                                              Cat\# 17-0112-82                                                          FACS (1:200)

  Antibody                                         PE/Cy7 anti-mouse monoclonal CD11b                 BioLegend                                                Cat\# 101216                                                              FACS (1:100)

  Antibody                                         PerCP-eFluor 710 anti-mouse monoclonal CD135       eBioscience                                              Cat\#46-1351-80                                                           FACS (1:200)

  Antibody                                         PerCP-eFluor710 anti-human/mouse monoclonal IRF4   eBioscience                                              Cat\# 46-9858-80                                                          FACS (1:200)

  Antibody                                         PE anti-human/mouse monoclonal IRF8                R and D Systems                                          Cat\# IC8447P                                                             FACS (1:200)

  Antibody                                         PE anti-mouse monoclonal IRF5                      Invitrogen                                               Cat\# PCS-201--012                                                        FACS (1:200)

  Antibody                                         PerCP anti-mouse monoclonal CD4                    BD Bioscience                                            Cat\# 553052                                                              FACS (1:200)

  Antibody                                         FITC anti-mouse monoclonal CD4                     BD Bioscience                                            Cat\# 553729                                                              FACS (1:200)

  Antibody                                         PE anti-mouse monoclonal IL-33Rα                   BioLegend                                                Cat\# 145303                                                              FACS (1:200)

  Antibody                                         PEcy7 anti-mouse monoclonal CD44                   eBioscience                                              Cat\# 25-0441-82                                                          FACS (1:200)

  Antibody                                         APC anti-mouse monoclonal CD62L                    eBioscience                                              Cat\# 17-0621-83                                                          FACS (1:200)

  Antibody                                         APC anti-mouse monoclonal FOXP3                    eBioscience                                              Cat\# 17-5773-82                                                          FACS (1:200)

  Antibody                                         PE anti-mouse monoclonal Dectin-1                  BioLegend                                                Cat\# 144303                                                              FACS (1:200)

  Antibody                                         anti-mouse monoclonal CD3e (2C11)                  BioXcell                                                 Cat\# BE0001-1FAB                                                         10 μg/ml

  Antibody                                         anti-mouse monoclonal CD28                         BioXcell                                                 Cat\# BE0015-5                                                            1 μg/ml

  Commercial assay or kit                          EasySep Mouse Naïve CD4+ T Cell Isolation Kit      StemCell Technologies                                    Cat\# 19765                                                               

  Peptide, recombinant protein                     Recombinant Mouse GM-CSF                           BioLegend                                                Cat\# 576302                                                              10 ng/ml

  Peptide, recombinant protein                     Recombinant Human GM-CSF                           BioLegend                                                Cat\# 572903                                                              100 ng/ml

  Peptide, recombinant protein                     TGF-β                                              R and D systems                                          Cat\# 240-B-002                                                           10 ng/ml

  Peptide, recombinant protein                     TNF-α                                              R and D systems                                          Cat\# 210-TA-005                                                          2.5 ng/ml

  Peptide, recombinant protein                     rhIL-4                                             BioLegend                                                Cat\# 574002                                                              100 ng/ml

  Chemical compound, drug                          Calcium ionophore A23187                           Sigma-Aldrich                                            Cat\# C7522                                                               180 ng/ml

  Chemical compound, drug                          CPT-cAMP                                           Sigma-Aldrich                                            Cat\# C3912                                                               50 μM

  Chemical compound, drug                          Prostaglandin E2                                   Sigma-Aldrich                                            Cat\# P5640                                                               10 μM

  Chemical compound, drug                          Forskolin                                          Sigma-Aldrich                                            Cat\# F6886                                                               10 μM

  Chemical compound, drug                          Pertussis toxin                                    Sigma-Aldrich                                            Cat\# P7208                                                               100 ng/ml

  Chemical compound, drug                          Phorbol 12-myristate 13-acetate                    Sigma-Aldrich                                            Cat\# P8139                                                               50 ng/ml

  Chemical compound, drug                          Ionomycin                                          Sigma-Aldrich                                            Cat\# I3909                                                               1 μM

  Chemical compound, drug                          Doxycycline                                        Sigma-Aldrich                                            Cat\# D9891                                                               200 ng/ml

  Chemical compound, drug                          CREB inhibitor (666-15)                            Millipore Sigma                                          Cat\# 5383410001                                                          1 μM

  Chemical compound, drug                          Cholera toxin                                      List biological laboratories                             Cat\# 101B                                                                1 μg/ml

  Chemical compound, drug                          Ovalbumin                                          Worthington Biochemical                                  Cat\# LS003054                                                            100 μg/ml

  Chemical compound, drug                          MHC class II OVA peptide                           GenScript                                                Cat\# RP10610                                                             1 μg/ml

  Chemical compound, drug                          HDM extract                                        Greer Laboratories                                       Cat\# XPB82D3A2.5                                                         

  Chemical compound, drug                          Rp-cAMP                                            BioLog                                                   Cat\# A002S                                                               50 μM

  Chemical compound, drug                          Rolipram                                           Tocris Bioscience                                        Cat\# 0905                                                                10 μM

  Chemical compound, drug                          CE3F4                                              Tocris Bioscience                                        Cat\# 4793                                                                10 μM

  Chemical compound, drug                          Curdlan                                            Wako Chemicals                                           Cat\# 034--09901                                                          10 μg/ml
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Mice and cells {#s4-1}
--------------

Gnas^ΔCD11c^ mice were produced in our laboratory by crossing of *Gnas* floxed mice (*Gnas*^fl/fl^) with CD11c-Cre mice as described previously ([@bib50]). To generate *Irf4*-deficient CD11c cells, *Irf4*^fl/fl^ mice were crossed to CD11c-Cre mice for at least four generations. Cre-mediated GFP expression was used to trace *Irf4* ablation with other markers (CD11c, CD11b and CD8α) in splenocytes ([@bib40]; [@bib61]). More than 96% of isolated cDC2s were GFP positive. The Cre^-^*Irf4*^fl/fl^ littermates were used as controls. IL17A-eGFP mice were bred to OT-II mice to yield IL17A-eGFP/OT-II mice. All mice were kept in a specific pathogen-free (SPF) facility. IL4-eGFP reporter (4Get) mice were originally made by Dr. R Locksley (University of California San Francisco) ([@bib64]) and were a gift from Dr. M Kronenberg (LAI, San Diego, CA). IL17A-eGFP mice were bred to OT2 mice to yield 4Get/OT2 and IL17A-eGFP/OT2 mice, respectively. All mice were kept in a specific pathogen-free (SPF) facility. *Irf4*-inducible (*Irf4^-/-^*) mice ([@bib74]) were bred by Dr. R Sciammas (University of California, Davis). *Irf5*^-/-^ mice were provided by Dr. I R Rifkin (Boston University) ([@bib93]; [@bib101]). *Il17a^-/-^*mice were obtained from Dr. Y Iwakura (The University of Tokyo, Japan) ([@bib70]).

OT-II T cells were isolated by magnetic beads (EasySep Mouse Naïve CD4^+^ T Cell Isolation Kit, StemCell Technologies) from a single cell suspension of splenocytes. Bone marrow (BM) cells were cultured in the presence of GM-CSF (10 ng/ml) for 7 days. Floating cells from the BM culture were applied to FACS-sorting (BD FACSAria II) and CD11c^+^CD135^+^ BM cells (BM-APCs) were used for co-culture with naïve OT-II T cells and transcription factor (TF) analysis by qPCR. cDC2 cells were isolated from single cell suspension of spleens. CD11c^+^CD11b^+^CD8α^-^ splenocytes ([@bib61]; [@bib105]) were isolated by FACS sorting and applied to co-culture and TFs analysis. cDC1 were isolated by FACS sorting of CD11c^+^CD11b^-^CD8α^+^ splenocytes and subjected to the same analysis described for cDC2.

OVA-specific immune responses in the cDC-OT-II co-culture {#s4-2}
---------------------------------------------------------

OVA-specific CD4^+^ T cell response was performed using the DC-OT-II co-culture system as described ([@bib50]). Briefly, CD11c^+^CD11b^+^CD8α^-^ splenocyte (cDC2s), CD11c^+^CD11b^-^CD8α^+^ splenocyte (cDC1s) or CD11c^+^CD135^+^ BM cells were isolated by FACS sorting as described above. cDC2s and cDC1s were loaded with OVA peptide (1 μg/ml) 2 hr before T cell addition and BM-APCs were cultured in complete RPMI 1640 containing OVA protein (100 μg/ml) for 16 hr. Various cAMP agonists indicated in the figures were added in the culture 16 hr before T cell engagement. Specially, curdlan (10 μg/ml) was treated for 24 hr before co-culture. For the IRF4 restoration in Irf4i cDC2s, 200 ng/ml doxycycline was added for 12 hr before co-culture. OT-II T cells were co-cultured with cDC2 (3 × 10^5^ cells) at 1:2 ratio in a round-bottom 96-well plate or with BM-APC (5 × 10^5^ cells) at 1:1 ratio in a 24-well plate in the serum-free culture medium supplemented with albumin. After 3 days of co-culture, OT-II T cells were stimulated with plate-bound anti-CD3/28 antibodies for 24 hr and then used by ELISA to measure cytokines levels or stimulated with PMA and ionomycin for 3 hr for the T cell lineage marker (qPCR).

Switch from memory Th2 to Th17 (Fate mapping) {#s4-3}
---------------------------------------------

Memory Th2 cells (TEM, CD44^+^CD62L^low^ or TCM, CD44^+^CD62L^high^) were generated by co-culturing of naïve IL-17GFP CD4^+^ OT-II cells with BM-APCs from Gnas^ΔCD11c^ mice for 3 days and then T1/ST2^+^ cells were sorted by FACS. T1/ST2^+^ cells were used for 2^nd^ co-culture with OVA peptide (1 μg/ml) loaded-CPT (50 μM) or Cholera toxin (1 μg/ml) treated WT cDC2s. After 3 days of 2^nd^ co-culture, IL-17GFP CD4^+^ OT-II T cells were stimulated with plate-bound anti-CD3/28 antibodies for 24 hr and then used for ELISA to measure cytokines levels or stimulated with PMA (50 ng/ml) and ionomycin (1 μM) for 6 hr for the GFP expression measurement by FACS.

Human DC-like cells differentiation {#s4-4}
-----------------------------------

Human myeloid leukemia cell line MUTZ-3 was acquired from Dr. Martin L. Yarmush (Rutgers University School of Engineering, Piscataway, New Jersey). MUTZ-3 cells were maintained and differentiated into DC-like cells as described previously ([@bib41]). Briefly, MUTZ-3 cells were cultured in α-MEM (Invitrogen, Carlsbad, CA, USA) supplemented with 20% Fetal bovine serum, 50 μM β-mercaptoethanol and 10% 5637 cell-conditioned media. For generation of DC-like cells, MUTZ-3 cells (10^5^ cells/ml, 2 ml medium/well) were cultured in growth media supplemented with GM-CSF (100 ng/ml, BioLegend, San Diego), TGF-β (10 ng/ml, R and D systems) and TNF-α (2.5 ng/ml, R and D systems) for 7 days. The human monocytic leukemia cell line, THP-1 was from ATCC. As described previously ([@bib8]), THP-1 cell line was maintained in RPMI 1640 supplemented with 10% FCS at a concentration of 2 × 10^5^ cells/ml. To induce differentiation, rhIL-4 (100 ng/ml) and rhGM-CSF (100 ng/ml) were added. Cells were cultured for 5 days to acquire the DC-like cell phenotype. Medium was exchanged every 2 days with fresh cytokine-supplemented medium. The human leukemia cell line, HL-60 was from ATCC. HL-60 cells were cultured in RPMI 1640 medium containing 10% FCS. For DC-like differentiation, HL-60 cells were incubated in the culture media together with calcium ionophore A23187 (180 ng/ml) and rhGM-CSF (100 ng/ml) for 24 hr, as described ([@bib108]). All cell line was regularly tested for mycoplasma contamination by PCR and negative for mycoplasma.

ELISA measurement of cytokines {#s4-5}
------------------------------

Cytokine levels in the supernatant were determined using ELISA kits for IL-4, IL-5, IL-10, IFN-γ, IL-1β, IL-6 and IL-17A (eBioscience, La Jolla, CA) following the manufacturer's instructions.

Flow cytometry and intracellular staining {#s4-6}
-----------------------------------------

The data were acquired by a C6 Accuri flow cytometer (BD Biosciences) and analyzed by FlowJo Software. For the staining of surface molecule, cells were washed with FACS buffer (2% FCS containing PBS) and incubated with the indicated antibodies on ice for 30 min. After two times of wash with FACS buffer, cells were used for analysis. For IRF4, IRF5 and IRF8 intracellular staining, surface marker stained cells were fixed and permeabilized using Cytofix/Cytoperm (BD Biosciences) and stained with Ab for 30 min. After 3 times of wash with permeabilization buffer, the intracellular levels of IRFs were analyzed in the different DC subsets. For the detection of GFP^+^ cells, harvested CD4^+^ T cells were stimulated with PMA (50 ng/ml) and ionomycin (1 μM) in the presence of GolgiStop (BD Pharmingen) for 6 hr before FACS analysis.

Adoptive transfer of cDC2s {#s4-7}
--------------------------

Adoptive transfer model was initially described by [@bib47]. Briefly, splenic cDC2s from WT donors were pulsed with HDM (50 μg/ml) or OVA (100 μg/ml), with and without CPT or Curdlan. After 24 hr incubation, the cDC2s were washed with PBS three times, re-suspended in PBS, and transferred into anesthetized WT or IL-17eGFP recipient mice i.n (5 × 10^5^ cells in 20 μl PBS) on day 0 and 14 ([@bib50]; [@bib55]). Mice were challenged by 12.5 μg HDM, or 25 μg OVA i.n. on day 19, 20 and 21. One day after the last challenge, mice were analyzed for airway hyper-responsiveness (AHR) to methacholine (MCh). Bronchoalveolar lavage (BAL) fluid was collected for cellular composition (light microscopy) and cytokine analysis. For cytokine analysis from lung tissue, lung single cell suspension was prepared from three lobes from each mouse as described ([@bib21]; [@bib50]) and stimulated with HDM (50 μg/ml) or OVA (200 μg/ml) for 3 days. Supernatant from the culture was applied to cytokine analysis by ELISA.

Quantitative PCR analysis {#s4-8}
-------------------------

Isolation of RNA was carried out using an RNA purification Kit (Thermo Fisher Scientific) according to the manufacturer's instructions. The cDNA was synthesized using Superscript III First-Strand system (Invitrogen). Quantitative PCR analysis was performed as described previously ([@bib50]). SYBR Green PCR Master Mix was used for real-time PCR (Thermo Fisher Scientific). Samples were run in triplicate and normalized by *Gapdh*. PCR for *Irf5* was performed using Taqman primers according to the manufacturer's instructions. Primer sequences are listed in previous study ([@bib50]) and additional sequences are:

1.  *Irf4*: F-AGATTCCAGGTGACTCTGTG, R-CTGCCCTGTCAGAGTATTTC,

2.  *Irf8*: F-CGCTGTAGGAAAAGCAGACC, R-CCTCCAACAACACAGGGAGT,

3.  *Klf4*: F-CTGAACAGCAGGGACTGTCA, R-GTGTGGGTGGCTGTTCTTTT,

4.  *Crem*: F-GCTGAGGCTGATGAAAAACA, R-GCCACACGATTTTCAAGACA,

5.  *Il23a*: F-TCCGTTCCAAGATCCTTCG, R-GAACCTGGGCATCCTTAAGC.

Expression profiling and genomic analysis {#s4-9}
-----------------------------------------

Total RNA was isolated from splenic cDC2 cells using RNeasy columns (Qiagen, Germantown, MD). Non-stranded sequencing libraries were prepared using Illumina TruSeq RNA library kits and sequenced on an Illumina Hi Seq2500 using a SE70 protocol (Illumina, San Diego, CA). ATACSeq was performed on splenic cDC2 cells by the UCSD Center for Epigenomics using a PE75 protocol. Raw sequenced reads were trimmed for adapter and bar-codes sequences and quality assessed using FastQC (<http://www.bioinformatics.babraham.ac.uk/projects/fastqc/>). Reads were aligned to the mm10 genome using STAR ([@bib20]) with mgcGene annotations (<https://genome.ucsc.edu/cgi-bin/hgTables>). Differential expression was determined using DESeq2 ([@bib3]) in SeqMonk (<http://www.bioinformatics.babraham.ac.uk>/projects/seqmonk/). ChIPseq reads were identified using the Cistrome Data Browser (<http://cistrome.org/db/#/>) then raw reads were downloaded from the Sequence Read Archive (<https://www.ncbi.nlm.nih.gov/sra>) using sratools (<https://ncbi.github.io/sra-tools/>). The reads were aligned with STAR ([@bib20]) then binding peaks identified using the HOMER suite (<http://homer.ucsd.edu/>). Differential ChIPseq and ATACseq peaks were analyzed using the getDifferentialPeaksReplicates.pl, annotatePeaks.pl and makeMetaGeneProfile.pl scripts, and motif analysis performed using the findMotifsGenome.pl script. The binding-expression predictions were run with BETA ([@bib99]). Histone modification co-localization, the transcription factor binding metagene analysis and the de novo motif identification were performed using HOMER. RNAseq, ChIPseq, ATACseq and histone modifications were visualized in IGV ([@bib80]). Heatmaps were generated using heatmap.2 in R. Transcriptional network and pathway enrichment analysis were performed in MetaCore (Genego, Clarivate Analytics, Philadelphia, PA).

Statistical analysis {#s4-10}
--------------------

Student's t-tests were used to analyze data sets with two groups (GraphPad Prism software). One- or two-way ANOVA were used for multiple groups. All data are represented as mean ± s.e.m unless indicated otherwise. p-values\<0.05 were considered signiﬁcant.

Study approval {#s4-11}
--------------

All the experimental procedures were approved by the UCSD-IACUC (\#S02240).
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###### Tables of transcriptional profiling (RNAseq).

Supplementary Table 1: Genes altered by CPT treatment of cDC2 Table shows genes altered in CPT-treated splenic cDC2 cells. RNAseq data was analyzed by DESeq2 using a FDR \< 0.05 multiple testing correction. Columns indicate gene symbol; chromosome; start and end positions of the gene; chromosome strand; stable Ensembl gene ID; description of gene; mean read counts for CPT-treated WT (CPT), untreated WT (UN), doxycycline-treated *Irf4^-/-^* (DOX), *Irf4^-/-^* (IRF4KO), and WT littermate (WT) cDC2 cells; fold change for CPT-treated versus untreated (FC); the log2-transformed fold change (log2FC); and the corrected p-value (FDR). Supplementary Table 2: Genes altered in *Irf4*^-/-^ cDC2 Table shows genes altered in splenic cDC2 cells from *Irf4^-/-^* mice. RNAseq data was analyzed by DESeq2 using a FDR \< 0.05 multiple testing correction. Columns indicate gene symbol; chromosome; start and end positions of the gene; chromosome strand; stable Ensembl gene ID; description of gene; mean read counts for CPT-treated WT (CPT), untreated WT (UN), doxycycline-treated *Irf4^-/-^* (DOX), *Irf4^-/-^* (IRF4KO), and WT littermate (WT) cDC2 cells; fold change for CPT-treated versus untreated (FC); the log2-transformed fold change (log2FC); and the corrected p-value (FDR). Supplementary Table 3: Genes altered in IRF4 overexpressing *Irf4^-/-^* cDC2 Table shows genes altered in splenic cDC2 cells from *Irf4^-/-^* mice that had been treated with doxycycline to over-express IRF4. RNAseq data was analyzed by DESeq2 using a FDR \< 0.05 multiple testing correction. Columns indicate gene symbol; chromosome; start and end positions of the gene; chromosome strand; stable Ensembl gene ID; description of gene; mean read counts for CPT-treated WT (CPT), untreated WT (UN), doxycycline-treated *Irf4^-/-^* (DOX), *Irf4^-/-^* (IRF4KO), and WT littermate (WT) cDC2 cells; fold change for CPT-treated versus untreated (FC); the log2-transformed fold change (log2FC); and the corrected p-value (FDR). Supplementary Table 4: Transcription factor networks derived from CPT-regulated genes. Table shows transcription factor networks generated using genes differentially expressed in CPT-treated cDC2 cells. Networks were generated using GeneGo's MetaCore software. Columns contain network number; transcription factor driving network (Network); gene ontology (GO) processes that are enriched for the network; total number of genes (nodes) in network; number of input differentially-expressed genes (seed nodes) in network; number of canonical pathways in the network; the p-value for the network (p-Value), the z-score (zScore) indicating the number of SDs from the mean for the network, and the z-score corrected for the interactions of non-seed nodes (gScore) for the network. Supplementary Table 5: Transcription factor networks derived from genes differentially expressed in *Irf4^-/-^* cDC2. Table shows transcription factor networks generated using genes differentially expressed in *Irf4^-/-^* cDC2 cells. Networks were generated using GeneGo's MetaCore software. Columns contain network number; transcription factor driving network (Network); gene ontology (GO) processes that are enriched for the network; total number of genes (nodes) in network; number of input differentially-expressed genes (seed nodes) in network; number of canonical pathways in the network; the p-value for the network (p-Value), the z-score (zScore) indicating the number of SDs from the mean for the network, and the z-score corrected for the interactions of non-seed nodes (gScore) for the network. Supplementary Table 6: Transcription factor networks derived from genes differentially expressed by over-expression of IRF4. Table shows transcription factor networks generated using genes differentially expressed in doxycycline-treated *Irf4^-/-^* cDC2 cells. Networks were generated using GeneGo's MetaCore software. Columns contain network number; transcription factor driving network (Network); gene ontology (GO) processes that are enriched for the network; total number of genes (nodes) in network; number of input differentially-expressed genes (seed nodes) in network; number of canonical pathways in the network; the p-value for the network (p-Value), the z-score (zScore) indicating the number of SDs from the mean for the network, and the z-score corrected for the interactions of non-seed nodes (gScore) for the network. Supplementary Table 7: Genes altered in both CPT-treated and *Irf4^-/-^* cDC2 Table shows genes differentially expressed in both CPT-treated and from *Irf4^-/-^* splenic cDC2 cells. RNAseq data was analyzed by DESeq2 using a FDR \< 0.05 multiple testing correction. Columns indicate gene symbol; chromosome; start and end positions of the gene; chromosome strand; stable Ensembl gene ID; mean read counts for CPT-treated WT (CPT), untreated WT (Untreated), doxycycline-treated *Irf4^-/-^* (DOX), *Irf4^-/-^* (IRF4-KO), and WT littermate (WT) cDC2 cells; the log2-transformed fold change for CPT-treated cDC2 (log2FC CPT/UN); the log2-transformed fold change for doxycycline-treated *Irf4*^-/-^ cDC2 (log2FC DOX/KO); the log2-transformed fold change for *Irf4*^-/-^ cDC2 (log2FC KO/WT); and the description of the gene. Supplementary Table 8: Genes altered in both *Irf4^-/-^* cDC2 and in the IRF4 over-expressing cDC2 Table shows genes differentially expressed in both *Irf4^-/-^* splenic cDC2 cells and in doxycycline-treated *Irf4^-/-^* cDC2. RNAseq data was analyzed by DESeq2 using a FDR \< 0.05 multiple testing correction. Columns indicate gene symbol; chromosome; start and end positions of the gene; chromosome strand; stable Ensembl gene ID; mean read counts for CPT-treated WT (CPT), untreated WT (Untreated), doxycycline-treated *Irf4^-/-^* (DOX), *Irf4^-/-^* (IRF4-KO), and WT littermate (WT) cDC2 cells; the log2-transformed fold change for CPT-treated cDC2 (log2FC CPT/UN); the log2-transformed fold change for doxycycline-treated *Irf4*^-/-^ cDC2 (log2FC DOX/KO); the log2-transformed fold change for *Irf4*^-/-^ cDC2 (log2FC KO/WT); and the description of the gene. Supplementary Table 9: Genes altered in CPT-treated, *Irf4^-/-^* cDC2, and IRF4 over-expressing splenic cDC2 Table shows genes differentially expressed in CPT-treated cDC2, *Irf4^-/-^* cDC2 cells, and *Irf4^-/-^* cDC2 treated with doxycycline to over-express IRF4. RNAseq data was analyzed by DESeq2 using a FDR \< 0.05 multiple testing correction. Columns indicate gene symbol; chromosome; start and end positions of the gene; chromosome strand; stable Ensembl gene ID; mean read counts for CPT-treated WT (CPT), untreated WT (Untreated), doxycycline-treated *Irf4^-/-^* (DOX), *Irf4^-/-^* (IRF4-KO), and WT littermate (WT) cDC2 cells; the log2-transformed fold change for CPT-treated cDC2 (log2FC CPT/UN); the log2-transformed fold change for doxycycline-treated *Irf4*^-/-^ cDC2 (log2FC DOX/KO); the log2-transformed fold change for *Irf4*^-/-^ cDC2 (log2FC KO/WT); and the description of the gene. Supplementary Table 10: Transcription factor networks derived from genes differentially expressed in CPT-treated cDC2, *Irf4^-/-^* cDC2, and in *Irf4^-/-^* cDC2 over-expressing IRF4. Table shows transcription factor networks generated using genes differentially expressed in CPT-treated cDC2, *Irf4^-/-^* cDC2 cells, and *Irf4^-/-^* cDC2 treated with doxycycline to over-express IRF4. Networks were generated using GeneGo's MetaCore software. Columns contain network number; transcription factor driving network (Network); gene ontology (GO) processes that are enriched for the network; total number of genes (nodes) in network; number of input differentially-expressed genes (seed nodes) in network; number of canonical pathways in the network; the p-value for the network (p-Value), the z-score (zScore) indicating the number of SDs from the mean for the network, and the z-score corrected for the interactions of non-seed nodes (gScore) for the network. Supplementary Table 11: Enrichment analysis using the 239 genes differentially expressed in CPT-treated cDC2, *Irf4^-/-^* cDC2, and in *Irf4^-/-^* cDC2 over-expressing IRF4. Table shows the top ten enriched pathways, process networks, and GO processes transcription factor networks generated using genes differentially expressed in CPT-treated cDC2, *Irf4^-/-^* cDC2 cells, and *Irf4^-/-^* cDC2 treated with doxycycline to over-express IRF4. Enrichment was performed using GeneGo's MetaCore software. Columns contain the pathway map, network, or process name; the total number of genes involved; the p-value (p-Value); the FDR corrected p-value (FDR); the number of differentially expressed genes in the pathway, network or process; and the gene symbols for these genes in the pathway, network, or process. Supplementary Table 12: Common genes encoding secreted proteins. Table shows the 239 differentially expressed genes common to CPT-treatment *Irf4*^-/-^ or IRF4 over-expression that are annotated to encode secreted proteins. Columns indicate gene symbol; chromosome; start and end positions of the gene; chromosome strand; stable Ensembl gene ID; description of the gene; mean read counts for CPT-treated WT (CPT), untreated WT (Untreated), doxycycline-treated *Irf4^-/-^* (DOX), *Irf4^-/-^* (IRF4-KO), and WT littermate (WT) cDC2 cells; the log2-transformed fold change for CPT-treated cDC2 (log2FC CPT/UN); the log2-transformed fold change for doxycycline-treated *Irf4*^-/-^ cDC2 (log2FC DOX/KO); the log2-transformed fold change for *Irf4*^-/-^ cDC2 (log2FC KO/WT); the FDR-corrected p-values (FDR); the Uniprot accession number; gene synonyms; the UniProt info; and the UniProt protein name. Table is separated into two panels for genes showing concordant versus discordant regulation by CPT and IRF4. Supplementary Table 13: Common genes encoding plasma membrane proteins. Table shows the 239 differentially expressed genes common to CPT-treatment *Irf4*^-/-^ or IRF4 over-expression that are annotated to encode plasma-membrane proteins. Columns indicate gene symbol; chromosome; start and end positions of the gene; chromosome strand; stable Ensembl gene ID; description of the gene; mean read counts for CPT-treated WT (CPT), untreated WT (Untreated), doxycycline-treated *Irf4*^-/-^ (DOX), *Irf4*^-/-^ (IRF4-KO), and WT littermate (WT) cDC2 cells; the log2-transformed fold change for CPT-treated cDC2 (log2FC CPT/UN); the log2-transformed fold change for doxycycline-treated *Irf4*^-/-^ cDC2 (log2FC DOX/KO); the log2-transformed fold change for *Irf4*^-/-^ cDC2 (log2FC KO/WT); the FDR-corrected p-values (FDR); the Uniprot accession number; gene synonyms; the UniProt info; and the UniProt protein name. Table is separated into two panels for genes showing concordant versus discordant regulation by CPT and IRF4. Supplementary Table 14: Chromatin accessibility by ATACseq. Table shows the genome-wide ATACseq peak enrichment for CPT-treated cDC2, *Irf4*^-/-^ cDC2, or IRF4 over-expressing *Irf4*^-/-^ cDC2. Sequence reads were analyzed using HOMER. Columns indicate peak-ID; chromosome; start and end positions of the peak; chromosome strand; peak score; the focus ratio for the region size; the location of the peak; the distance to nearest transcription start site (TSS); the nearest promoter ID; the Entrez ID; the nearest Unigene ID; the nearest RefSeq gene; the nearest Ensembl gene ID; the gene symbol; gene aliases; the description of the gene; the type of gene; the sequence tag counts; and the peak p-value and adjusted p-value. Table is split into three panels for CPT-treated, *Irf4*^-/-^ enriched, or IRF4 over-expression enriched peaks. Supplementary Table 15: ChIPseq and ATACseq datasets used in this paper. Table shows ChIP target, SRA file numbers, cells used to generate data, and publication reference. Supplementary Table 16: IRF4-super enhancers in BMDC. Table shows the IRF4 super enhancers derived from IRF4 ChIPseq data. Sequence reads were analyzed using HOMER. Columns indicate peak-ID; chromosome; start and end positions of the peak; chromosome strand; peak score; the focus ratio for the region size; the location of the peak; the distance to nearest transcription start site (TSS); the nearest promoter ID; the Entrez ID; the nearest Unigene ID; the nearest RefSeq gene; the nearest Ensembl gene ID; the gene symbol; gene aliases; the type of gene; and the description of the gene.

Data availability {#s7}
=================

All data supporting the findings of this study are available within the paper or in the supplementary materials.
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1\) One of the most critical issues is the causative relationship between cAMP and IRF4. The current data suggest that the effects of cAMP activation and IRF4 deletion are highly similar and phenocopy each other, but such data are correlative. The authors need to establish whether IRF4 truly mediates cAMP signaling, e.g. by expressing IRF4 in cAMP-treated DCs.

2\) It is somewhat surprising that ATAC-Seq experiments did not reveal major effects on the selective genes. The authors should do a global analysis to test the extent of altered chromatin accessibility, and the enrichments of transcription factors. Also, conclusions derived from RNA-Seq data are inferred, and additional data should be included to validate these results.

3\) The authors need to examine IRF4 expression in a more detailed way, e.g. by flow cytometry and western blot analysis.

4\) The paper is difficult to read, and the authors should revise it for better clarity. They should include a model to highlight the major findings. Also, the Discussion section is too long and should be streamlined.

The authors should include the number of independent experiments in the figure legends.

As recommended, we included the number of independent experiments in each figure legends.

*Reviewer \#2:*

The authors present compelling data examining the molecular mechanisms underlying the Th2 and Th17 inducing properties of cDC2s. This work is of great relevance to the field, as we continue to developmentally and functionally define cDC lineages. The authors show that PPR-independent pathways involving cAMP-PKA-CREB signaling as well as a PRR-dependent pathway repress IRF4 and KLF4 and lead to pro-Th17 priming phenotype of cDC2. The authors present RNA-seq, ChIP-seq and ATAC-Seq data that advances our understanding of the function of IRF4 generally as well as how cAMP ultimately leads to pro-Th17 gene expression changes. Finally, the authors demonstrate functional relevance to their in vitro findings by adoptive transfer of CPT and Curdlan treated cDC2 within an HDM model, which revealed a Th17 bias and neutrophilic infiltration. While the data presented here is quite complete, I do have some suggestions that would strengthen the claims the authors are making.

1\) The IRF4 FACS staining is not uniform throughout the paper. In some cases, it appears that the cDC2 population has a bimodal expression pattern of IRF4 with two peaks on the histogram, while others there is a slight shift. The authors should include a cDC1 control in all histogram plots, which should be low but not negative for IRF4 in order to appreciate the true IRF4 positivity of the cDC2 population. In addition, perhaps MFI would be a better way to measure IRF4 shifts in cDC2 since they should be homogenous as a population.

2\) In regards to Figure 1I-M, gating for Th2EM cells should be shown and T1/ST2^+^ cells should be described more thoroughly. Have the authors excluded the possibility that these cells are T regulatory cells? FoxP3^+^ cells have also been described to express ST2. What happens to Foxp3 levels in T1/ST2 OT2 cells with co-culture of CPT- or CT-treated cDC2s?

3\) In regards to data collected on BM-APCS, it is well established that DC progenitors in the bone marrow have lineage commitment towards pDC, cDC1, and cDC2 identity. If there is a pro-Th17 effect of CPT on CD135^+^ CD11c^+^ BM-DC, which contains some pre-DC population, this may suggest that there would be subset skewing in mice that lack cAMP production within DC. Thus, do the GNASΔCD11c mice have any subset skewing in peripheral splenic DC populations, i.e. what are the percentages of cDC1, cDC2, and pDC in these mice?

4\) Do curdlan or cAMP signaling promote Notch2 expression in cDC2? This could be another factor in addition to IRF5 that promotes the pro-Th17 properties of cDC2.

\[Editors\' note: further revisions were suggested prior to acceptance, as described below.\]

Thank you for submitting your article \"Inhibition of IRF4 in dendritic cells by PRR-independent and -dependent signals inhibit Th2 and promote Th17 responses\" for consideration by *eLife*. Your article has been reviewed by a peer reviewer, and the evaluation has been overseen by a Reviewing Editor and Tadatsugu Taniguchi as the Senior Editor. The reviewers have opted to remain anonymous.

The revisions have addressed most of the reviewer concerns, but there is a remaining point of reviewer 1 that needs to be addressed.

*Reviewer \#1:*

The revised manuscript has largely addressed my questions. However, for my original point 4, the presentation of the data in Figure 4---figure supplement 1 is not clear to this reviewer. The authors should double check their data and interpretation, ideally including the control groups (CPT treatment alone, without DOX, appears to be missing), and all relevant statistical comparisons to fully support their conclusions. Otherwise, they should tone down their conclusions.

10.7554/eLife.49416.sa2

Author response

> Reviewer \#1:
>
> This manuscript reveals the interaction of cAMP signaling and IRF4 in DC function, and the heterogeneity of cDC2 cells. The results are of interest, but there are issues for the authors to address to improve the overall impact.
>
> 1\) One of the most critical issues is the causative relationship between cAMP and IRF4. The current data suggest that the effects of cAMP activation and IRF4 deletion are highly similar and phenocopy each other, but such data are correlative. The authors need to establish whether IRF4 truly mediates cAMP signaling, e.g. by expressing IRF4 in cAMP-treated DCs.

As the reviewer mentioned, cAMP activation and IRF4 deletion showed a similar phenotype. In the manuscript, we reasoned that increased cAMP inhibits the IRF4 expression, which subsequently induces Th17 differentiation. We introduced several cAMP-specific inhibitors that clarified the relationship between cAMP and IRF4 expression (Figure 1---figure supplement 4).

We further investigated the relationship between IRF4 and cAMP using IRF4 inducible mice on *Irf4*^-/-^ background (*Irf4-*inducible (*Irf4^-/-^*), Irf4i). BM-APC from Irf4i mice were treated with Doxycycline (Dox.) for the reconstitution of IRF4 and then we treated those cells with CPT. IRF4 expression was significantly increased by Dox treatment, but the subsequent CPT treatment did not change the restored IRF4 expression ([Author response image 1A](#respfig1){ref-type="fig"}). We also used these cells for the co-culture with OT-II T cells. IRF4^-/-^ BM-APC induced Th17 differentiation spontaneously and the increased in IL-17 was suppressed by the recovered IRF4 expression by Dox treatment ([Author response image 1B](#respfig1){ref-type="fig"}). In contrast, reconstituted IRF4 expression in BM-APC induced Th2 differentiation (i.e., IL-5, [Author response image 1C](#respfig1){ref-type="fig"}). However, as CPT did not change the restored IRF4 expression, decreased Th17 and increased Th2 differentiation by IRF4 reconstitution were not changed by CPT treatment. These results indicate that sustained expression of IRF4 in DC mitigate the effects of CPT on cell function. We added this data in the Figure 4---figure supplement 1.

![The impact of sustained IRF4 expression on cAMP induced Th17 bias.\
(**A**) IRF4 expression in the WT and Irf4i BM-APCs treated with or without doxycycline (Dox, 200 ng/ml) for 16 hour. After the Dox treatment cells were washed and treated with CPT (50 μM) for 48 hour. (**B, C**) IL-17A and IL-5 levels from the re-stimulated OT-II cells co-cultured with BM-APCs from WT and Irf4i mice under the conditions described above. Data are mean ± s.e.m, n=3 in each group; \*p\<0.05, **\#** p\<0.05 compared to WT untreated.](elife-49416-resp-fig1){#respfig1}

> 2\) It is somewhat surprising that ATAC-Seq experiments did not reveal major effects on the selective genes. The authors should do a global analysis to test the extent of altered chromatin accessibility, and the enrichments of transcription factors. Also, conclusions derived from RNA-Seq data are inferred, and additional data should be included to validate these results.

The ATAC-seq analysis of cDC2 that we performed was indeed a global analysis. The complete data is now included in supplementary data and the sequence files uploaded to SRA. The ATACseq data were analyzed using the HOMER suite for differences between CPT treatment of WT cDC2, *Irf4^-/-^* and WT cDC2, and Doxycycline-treated *Irf4*-inducble (*Irf4^-/-^*) cDC2. The CPT-treated WT cDC2 did not show any significant changes in ATACseq peaks; the *Irf4^-/-^* cDC2 gave 1 differential peak; and the IRF4 re-expressed *Irf4*^-/-^ cDC2 gave 9 differential peaks. Hence, we concluded that cAMP signaling and IRF4 do not cause major alterations in chromatin accessibility.

> 3\) The authors need to examine IRF4 expression in a more detailed way, e.g. by flow cytometry and western blot analysis.

In the manuscript we submitted, we already showed the IRF4 expression in cDC2 or BM-APC by using flow cytometry (Figure 1 and Figure 4, Figure 1---figure supplement 3 and Figure 4---figure supplement 1). However, to make the data clear we added MFI value of each group. Furthermore, we check the decreased IRF4 expression by CPT treatment by using western blot ([Author response image 2](#respfig2){ref-type="fig"}).

![Decreased IRF4 expression by CPT treatment in WT cDC2.\
WT cDC2 were treated with CPT (50 μM) for 48 hour and IRF4 were analyzed by western blot.](elife-49416-resp-fig2){#respfig2}

> 4\) The paper is difficult to read, and the authors should revise it for better clarity. They should include a model to highlight the major findings. Also, the Discussion section is too long and should be streamlined.

As recommended, we generated the graphical summary to highlight the finding ([Author response image 3](#respfig3){ref-type="fig"}) and added in the Figure 4I. We also rewrote the manuscript to increase clarity and shorten the Discussion section.

![A schematic diagram of Th2 inhibition and Pro-Th17 induction by PRR-independent and -dependent signals.](elife-49416-resp-fig3){#respfig3}

> The authors should include the number of independent experiments in the figure legends.

As recommended, we included the number of independent experiments in each figure legends.

> Reviewer \#2:
>
> The authors present compelling data examining the molecular mechanisms underlying the Th2 and Th17 inducing properties of cDC2s. This work is of great relevance to the field, as we continue to developmentally and functionally define cDC lineages. The authors show that PPR-independent pathways involving cAMP-PKA-CREB signaling as well as a PRR-dependent pathway repress IRF4 and KLF4 and lead to pro-Th17 priming phenotype of cDC2. The authors present RNA-seq, ChIP-seq and ATAC-Seq data that advances our understanding of the function of IRF4 generally as well as how cAMP ultimately leads to pro-Th17 gene expression changes. Finally, the authors demonstrate functional relevance to their in vitro findings by adoptive transfer of CPT and Curdlan treated cDC2 within an HDM model, which revealed a Th17 bias and neutrophilic infiltration. While the data presented here is quite complete, I do have some suggestions that would strengthen the claims the authors are making.
>
> 1\) The IRF4 FACS staining is not uniform throughout the paper. In some cases, it appears that the cDC2 population has a bimodal expression pattern of IRF4 with two peaks on the histogram, while others there is a slight shift. The authors should include a cDC1 control in all histogram plots, which should be low but not negative for IRF4 in order to appreciate the true IRF4 positivity of the cDC2 population. In addition, perhaps MFI would be a better way to measure IRF4 shifts in cDC2 since they should be homogenous as a population.

Based on the IRF4 FACS staining, BM-APCs showed homogeneous IRF4^+^ population, but there are two populations with different IRF4 expression level in cDC2. It seems like that the reduction of IRF4 by CPT is mainly happening in the IRF4^high^ population (Figure 1H and Figure 1---figure supplement 3). As reviewer recommended, we added cDC1 control in the data in which showed the shift of IRF4 by CPT in cDC2 cells ([Author response image 4](#respfig4){ref-type="fig"}) and we replaced the previous data in Figure 1H. The reduction of IRF4 by CPT in Gnas^ΔCD11c^ cDC2 was also showed with cDC1 control. Besides, for the clear data presentation, we added MFI value in flow cytometry data.

![Intracellular staining of IRF4 in WT cDC1 and cDC2s treated with or without CPT for 48 hour.](elife-49416-resp-fig4){#respfig4}

> 2\) In regards to Figure 1I-M, gating for Th2EM cells should be shown and T1/ST2^+^ cells should be described more thoroughly. Have the authors excluded the possibility that these cells are T regulatory cells? FoxP3^+^ cells have also been described to express ST2. What happens to Foxp3 levels in T1/ST2 OT2 cells with co-culture of CPT- or CT-treated cDC2s?

The T1/ST2 pathway was originally described in Th2 immunity, but recent studies provided evidence for the role of T1/ST2 pathway on the Treg cells (Pastille et al., 2019). We followed the reviewer's suggestion and confirmed the FOXP3 expression in the T1/ST2^+^ cells. More than 96% of T1/ST2^+^ cells were effector memory T (TEM, CD44^+^ CD62L^low^) and these cells showed less than 1% of FOXP3 expression ([Author response image 5A](#respfig5){ref-type="fig"}). We also analyzed FOXP3 expression in the T cells from the second co-culture with CT- or CPT treated cDC2 and most of T cells were FOXP3 negative ([Author response image 5B](#respfig5){ref-type="fig"}). In our previous study, we also confirmed that co-cultured OT-II T cells with Gnas^ΔCD11c^ BMAPCs did not show any change in the Foxp3 mRNA expression^2^. This data indicates that the cells we differentiated and used for the second co-culture are very unlikely Treg cells. We added this result in the Figure 1---figure supplement 2.

![FOXP3 expression in T1/ST2^+^ cells.\
OT-II CD4^+^ T cells were co-cultured with Gnas^ΔCD11c^ BM-APCs to generate memory Th2 cells (first co-culture). From the first co-culture, T1/ST2^+^ cells were FACS sorted and then used for co-culture with WT cDC2s pretreated with or without CPT or Cholera toxin (CT) (second co-culture). (**A**) Memory T cell marker and FOXP3 were analyzed in the first co-cultured T cells. (**B**) FOXP3 were analyzed in the second co-cultured T cells.](elife-49416-resp-fig5){#respfig5}

> 3\) In regards to data collected on BM-APCS, it is well established that DC progenitors in the bone marrow have lineage commitment towards pDC, cDC1, and cDC2 identity. If there is a pro-Th17 effect of CPT on CD135^+^ CD11c^+^ BM-DC, which contains some pre-DC population, this may suggest that there would be subset skewing in mice that lack cAMP production within DC. Thus, do the GNASΔCD11c mice have any subset skewing in peripheral splenic DC populations, i.e. what are the percentages of cDC1, cDC2, and pDC in these mice?

We followed the reviewer's suggestion and checked the percentage of cDC1, cDC2, and pDC in GNAS^fl/fl^ and GNAS^ΔCD11c^ mice. The pDC population was similar in both GNAS^fl/fl^ and GNAS^ΔCD11c^ mice, but GNAS^ΔCD11c^ mice showed higher cDC2 and lower cDC1 percentage compared to GNAS^fl/fl^. This data with the higher IRF4 expression in the GNAS^ΔCD11c^ cDC2 (Figure 1---figure supplement 3) supports pro-Th2 phenotype of GNAS^ΔCD11c^ mice which we already reported (Lee et al., 2015).

![DC composition in the GNAS^fl/fl^ and GNAS^ΔCD11c^ mice.\
Splenocytes were isolated from GNAS^fl/fl^ and GNAS^ΔCD11c^ mice and used for the analysis for pDCs and cDCs population.](elife-49416-resp-fig6){#respfig6}

> 4\) Do curdlan or cAMP signaling promote Notch2 expression in cDC2? This could be another factor in addition to IRF5 that promotes the pro-Th17 properties of cDC2.

Recent studies have divided the cDC2 lineage into Th2-inducing (IRF4^+^/KLF4^+^), and Th17-inducing (IRF4^+^/NOTCH2^+^) subpopulations (Tussiwand et al., 2015; Bedoui and Heath, 2015). We followed the reviewer's suggestion and checked the Notch2 expression on cDC2 after CPT treatment. As a result, the expression of Notch 2 was increased in CPT treated cDC2.

![Notch 2 expression on cDC2 after CPT treatment.\
Splenocytes were isolated from WT mice and treated with CPT (50 μM) for 24hour and then Notch 2 expression on cDC2 was analyzed by FACS.](elife-49416-resp-fig7){#respfig7}

Additional references:

Pastille, E. et al. The IL-33/ST2 pathway shapes the regulatory T cell phenotype to

promote intestinal cancer. Mucosal Immunol 12, 990-1003, doi:10.1038/s41385-019-

0176-y (2019).

> \[Editors\' note: further revisions were suggested prior to acceptance, as described below.\]
>
> The revisions have addressed most of the reviewer concerns, but there is a remaining point of reviewer 1 that needs to be addressed.
>
> Reviewer \#1:
>
> The revised manuscript has largely addressed my questions. However, for my original point 4, the presentation of the data in Figure 4 ---figure supplement 1 is not clear to this reviewer. The authors should double check their data and interpretation, ideally including the control groups (CPT treatment alone, without DOX, appears to be missing), and all relevant statistical comparisons to fully support their conclusions. Otherwise, they should tone down their conclusions.

We agree with reviewer's comment that our conclusion without appropriate control group is not persuasive. We already had the data which was not included in the previous version. As recommended, we added the result of the control group, CPT without Dox treatment. Unlike in WT BM-ACPs, CPT treatment did not change the expression of IRF4 in IRF4i BM-APCs without Dox ([Author response image 8A](#respfig8){ref-type="fig"}, green-dotted line). We also added IRF4 expression in the WT BM-APCs with Dox and CPT treatment, which is similar with CPT only group ([Author response image 8A](#respfig8){ref-type="fig"}, orange-dotted line). In addition, we added the T cell differentiation results that CPT treatment without Dox induced Th17 and inhibited Th2 in WT but not in IRF4i BM-APCs ([Author response image 8B](#respfig8){ref-type="fig"}). The statistical comparisons were also added to support out conclusion. With the addition of these data, we can suggest that sustained expression of IRF4 in DCs can blunt the effects of cAMP on their function. We updated the Figure 4---figure supplement 1 with new data and did not change the manuscript.

![Decreased IRF4 expression in BM-APCs promotes pro-Th17 phenotype and sustained IRF4 expression blocks cAMP-induced Th17 bias.\
(**A**) IRF4 expression in the WT and Irf4i BM-APCs treated with or without doxycycline (Dox, 200 ng/ml) for 16 hour. After the Dox treatment cells were washed and treated with CPT (50 μM) for 48 hour. (**B, C**) IL-17A and IL-5 levels from the re-stimulated OT-II cells co-cultured with BM-APCs from WT and Irf4i mice under the conditions described above. Data are mean ± s.e.m, n=3 in each group; **\***p\<0.05, **\#** p\<0.05 compared to WT-untreated.](elife-49416-resp-fig8){#respfig8}
